x e n o b i o t i c a , 1998, v o l . 28, n o . 12, 1203± 1253
Inhibition and induction of hum an cytochrom e P450
(CYP) enzym es
O. PELKONEN ‹ *, J. MAÈ ENPAÈ AÈ Œ , P. TAAVITSAINEN ‹ ,
A. RAUTIO ‹ and H. RAUNIO ‹
‹ Department of Pharmacology and Toxicology, University of Oulu, FIN-90220 Oulu,
FinlandŒ Clinical Research, Leiras OY, PO Box 325, FIN-00101, Helsinki, Finland
Received January 1998
Introduction
Detailed knowledge of metabolism of drugs is crucial for two main reasons.
First, metabolism determines to a large extent pharmacokinetic behaviour, inter-
individual variability and interactions of a drug, all matters of great importance
in drug treatment. Second, diå erences in metabolism are also often behind the
diæ culties in the extrapolation from animals to man, which is a serious obstacle in
drug testing and development.
There is a large number of factors aå ecting drug metabolism and they are usually
classi® ed into genetic and non-genetic host and environmental factors. In the last
category, chemical exposures, including drug treatment, occupational exposure to
chemicals or environmental pollution can lead either to induction or inhibition of
drug metabolism.
Induction is de® ned as the increase in the amount and activity of a drug-
metabolizing enzyme, which is a long-term (hours and days) consequence of a
chemical exposure. Inhibition of drug metabolism in general may mean either an
acute decrease of metabolism of a particular substrate by another simultaneously
present chemical or a time-dependent decrease in the amount of a drug-metabolizing
enzyme by several factors, such as a chemical injury or a disease process. In this
review, we will deal only with interactions at the level of enzymes.
Previously, the study of induction and inhibition of drug metabolism was largely
empirical and phenomenological, and prediction beyond the compounds under
study was very diæ cult, if at all possible. During the past decade, however, and
particularly as a consequence of the detailed knowledge obtained about cytochrome
P450 (CYP) enzymes, both induction and inhibition can be understood on a detailed
mechanistic basis and the predictability of pharmacological and toxicological
consequences has become possible.
As to clinical consequences of induction and inhibition, the nature of the
products determine the outcome. If the reaction to be studied leads to inactive
product(s), induction results in attenuation and inhibition results in exaggeration of
the eå ects of a drug. If the product is active, either pharmacologically or
toxicologically, the reverse outcome is observed.
This review covers the phenomena of induction and inhibition of human CYPs
and concentrates upon quantitative aspects of in vitro and in vivo studies. This
* Author for correspondence.
0049 ± 8254 } 98 $12.00 ’ 1998 Taylor & Francis Ltd
1204 O. Pelkonen et al.
approach is hoped to provide a background for quantitative extrapolation of results
obtained from in vitro experimental systems to the in vivo situation, both for
induction and inhibition.
Characterization of human CYPs in the liver
Hepatic patterns of CYP enzymes
Since the 1980s our knowledge on speci® c forms of the P450 system in human
tissues has increased enormously. As a result of protein puri® cation, antibody
production, immunoinhibition, use of panels of substrates and inhibitors, and the
cloning, sequencing and heterologous expression of CYP cDNAs, a detailed
knowledge on speci® c properties of enzymes has been achieved. For further
information see the recent extensive reviews of Nebert (1989, 1991), Gonzalez
(1990, 1992), Guengerich (1992, 1994) and Wrighton and Stevens (1992).
A schematic presentation of some pertinent characteristics of the major human
hepatic CYP enzymes is given in ® gure 1. This qualitative ® gure serves as a
background and a synopsis for the sections dealing with quantitative aspects of
inhibitors and inducers with special emphasis on CYP speci® city and on semi-
quantitative extrapolation.
From the pharmacological and toxicological point of view, each enzyme can be
characterized on the basis of more or less selective substrates, inhibitors and
inducers. The relative amounts of various enzymes are naturally of importance, but
it should be kept in mind that the kinetic characteristics of enzymes towards
particular substrates and inhibitors are actually of importance for metabolism and
clearance of drugs and for metabolic interactions.
Interindividual variability of CYP enzymes
A phenomenon that cannot be overemphasized in the ® eld of xenobiotic
metabolism is interindividual variability, which results in very individualized
patterns of enzyme composition and hence metabolic activities. Permanent
determinants causing variability are genetic factors, which result in pharmaco-
kinetically distinct subpopulations, for example extensive and poor metabolizers
due to polymorphisms in CYP2D6 (Meyer 1994) and CYP2C19 (Goldstein and De
Morais 1994). It seems probable that there is at least some element of genetic
component in the variability of every CYP-associated activity (Pelkonen and Raunio
1997). On the other hand, numerous environmental factors add further variation,
which are not usually permanent, but transient. Induction and inhibition are
typically transient environmental factors, although it seems clear that the extent
(and maybe also the pattern) of induction may be determined by genetic factors.
Figure 1 depicts schematically the situation in the liver. There are some
enzymes, such as CYP2F1 and CYP4B1, that are expressed almost exclusively in
certain extrahepatic tissues (Raunio et al. 1995). Some enzymes, CYP1A1 (Raunio
et al. 1995) and CYP1B1 (Sutter et al. 1994, Hakkola et al. 1997) foremost, seem to
be present and } or induced mainly (if not solely) in extrahepatic tissues and are
therefore unlikely to be quantitatively of great importance in pharmacokinetics. The
rest of the CYP forms display a substantial variability, which has to be taken into
consideration in in vitro± in vivo extrapolation, but this is seldom currently done.
P450 inhibition and induction in man 1205
CY
P3A
4/5/
7
Dex
trom
etho
rpha
n
Fig
ure
1.
Sch
emat
icre
pre
sen
tati
on
of
hu
man
hep
atic
P4
50
enzy
mes
wit
hm
od
elsu
bst
rate
s,in
hib
itors
and
ind
ucer
s(m
od
i®ed
from
Pel
ko
nen
and
Bre
imer
19
94).
Th
esi
zeof
the
cir
cles
isro
ugh
lyp
rop
ort
ion
alto
the
rela
tive
am
ou
nts
inh
um
an
liv
er.B
roken
circ
les
ind
icat
eth
atth
ep
rese
nce
of
enzy
mes
isu
ncer
tain
,o
rvery
low
,or
may
app
ear
on
lyaf
ter
ind
ucti
on
.
1206 O. Pelkonen et al.
Table 1. Compounds and reactions claimed to demonstrate a high degree of human CYP speci® city.
CYP Preferred substrate and reactionK
m( l m )
Vmax
(nmol }mg 3 h) Reference
1A2 phenacetin O-deethylation 30 800 Bourrie et al. (1996)
ethoxyresoru® n O-deethylation 0.2 3.6 Bourrie et al. (1996)2A6 coumarin 7-hydroxylation 0.4 50 Pearce et al. (1992)
Bourrie et al. (1996)2B6 4-tri¯ uoro-7-ethoxycoumarin
O-deethylase
7 20 Buters et al. (1993)
2C8 taxol hydroxylation 18 50 Harris et al. (1994)
Sonnichsen et al. (1995)2C9 tolbutamide methylhydroxylation 400 15 Knodell et al. (1987)
Bourrie et al. (1996)diclofenac hydroxylation 4 45 Transon et al. (1996)
S-warfarin 7-hydroxylation 4 0.5 table 62C19 S-mephenytoin 4-hydroxylation 60 5 Kato et al. (1992)
Chiba et al. (1993)Relling et al. (1989)
omeprazole oxidation 10 6 Andersson et al. (1993)2D6 debrisoquine 4-hydroxylation 165 2 Boobis and Davies (1984)
Narimatsu et al. (1993)dextromethorpan O-deethylation 5 5 Fischer et al. (1992)
Transon et al. (1996)Rodrigues and Roberts (1997)
Bourrie et al. (1996)Kerry et al. (1994)
Ching et al. (1995)Le Guellec et al. (1993)
bufuralol 1´-hydroxylation 40 12 Boobis and Davies (1984)Halliday et al. (1995)
Yamazaki et al. (1994)2E1 chlorzoxazone 6-hydroxylation 40 90 Peter et al. (1990)
aniline 4-hydroxylation 15 90 Bourrie et al. (1996)3A4 testosterone (steroid) 6b-
hydroxylation
47 25 Waxman et al. (1983)
midazolam 1-hydroxylation 4 50 Kronbach et al. (1989)
Schmider et al. (1995)Ghosal et al. (1996)
Transon et al. (1996)nifedipine dehydrogenation 15 900 Bourrie et al. (1996)
Km
and Vmax
are approximate and some are con® rmed and modi® ed by our own unpublished studies.
Two subfamilies, namely CYP2C and CYP3A, are somewhat problematic
because they contain several closely related enzymes and there is still some
uncertainty about the assignment of speci® c activities with speci® c forms.
Substrate and inhibitor selectivity
From the point of view of this review, the most interesting characteristics of CYP
enzymes are substrate speci® city and inhibitor selectivity and in tables 1 and 2
several ` speci® c ’ or ` diagnostic ’ substrates and inhibitors have been listed, as they
are currently used. It must be stressed here that speci® city has in most cases only
a relative meaning, as will be later shown for some of these compounds. The term
` selectivity ’ should, in principle, be more appropriate. For example, substrates
which earlier were often used as ` isoform-speci® c ’ (at the time when the dichotomy
was principally between cytochromes P448 and P450), such as benzo(a)pyrene or
P450 inhibition and induction in man 1207
Table 2. Enzyme-speci® c ` diagnostic ’ inhibitory probes for human P450 enzymes.
CYP Inhibitor
Target CYP
Inhibition(K
i, l m )
Next sensitiveCYP (K
i, l m ) References
1A2 furafylline 0.7 " 10 Bourrie et al. (1996)
Clarke et al. (1994)¯ uvoxamine 0.2 8.2 (CYP2D6) Nemeroå et al. (1996)
2A6 methoxsalen 0.3 2 (CYP2E1) Ma$ enpa$ a$ et al. (1994)Yamazaki et al. (1992)
pilocarpine 4 " 10 (CYP2C9) Bourrie et al. (1996)2C9 sulfaphenazole 0.3 " 25 Bourrie et al. (1996)
2C19 teniposide 12 not known Relling et al. (1989)¯ uconazole 2 8 (2C9) Kunze et al. (1996)
2D6 quinidine 0.06 10 (3A4) Bourrie et al. (1996)Guengerich et al. (1986)
2E1 diethyldithio-carbamate
2 7 (CYP2A6) Yamazaki et al. (1992)
3A4 troleandomycin 18 ND* Zhou et al. (1993)ketoconazole 0.1 " 10 Bourrie et al. (1996)
Schmider et al. (1995)gestodene 7 ND* Guengerich et al. (1992)
ND, not determined.
benzphetamine, are in fact not very speci® c (Levin 1990, Soucek and Gut 1992).
Later on, research has been directed towards ® nding truly enzyme-speci® c
substances, or compounds which are metabolized at speci® c positions by speci® c
enzymes, e.g. testosterone (Waxman et al. 1983, 1991) or warfarin (Kaminsky 1989,
Rettie et al. 1989). Obviously ` enzyme-speci® city ’ is not a suæ cient prerequisite
enough for a substance that is intended to be used also in vivo, but it is an important
starting point.
With respect to inhibitors of enzyme activity, many substances are relatively
non-speci® c and even those claimed to be enzyme-speci® c usually have aæ nity to
other enzymes, although this occurs only at higher concentrations (table 2). One
good example is cimetidine, a well-known inhibitor of P450-linked reactions
(Puurunen et al. 1980). It has been shown that cimetidine interacts with at least
human hepatic CYP1A, 2C, 2D, 2E and 3A forms, but with widely variable aæ nities
(Knodell et al. 1991).
Further information on P450 substrates and inhibitors can be found in reviews
by Testa and Jenner (1981), Gonzalez (1992), Murray (1992), Vesell (1993),
Rodriguez (1994) and Guengerich (1995).
CYP speci® city of metabolism of a particular drug
A prerequisite for rational study and prediction of metabolic interactions is the
knowledge of CYP speci® city of metabolism or aæ nity of the compound under
study. Currently there is a number of approaches available to study of the role of
known CYPs in the metabolism and aæ nity of any xenobiotic. More extensive
coverage of these approaches can be found in recent reviews (Rodrigues 1994).
A simple approach is to study the inhibitory eå ect of a compound on model
reactions (table 1) catalysed by human liver microsomes or recombinant enzymes. If
a compound inhibits a particular activity, it has a certain aæ nity towards the
enzyme, although it is not possible to tell whether it is metabolized. If the primary
1208 O. Pelkonen et al.
metabolic routes of a compound have been elucidated and a method is available for
their quantitation in in vitro incubations, it is possible to employ ` diagnostic ’
inhibitors (table 2) and to look which of them, and at which concentrations, inhibit
metabolic routes. It is also possible to use enzyme-speci® c antibodies and to test
which metabolic routes are inhibited and to what extent by a particular anti-CYP
antibody. In a panel of human liver microsomes it is possible to correlate the
metabolism of a compound under study with the activities of CYP-speci® c model
reactions and thus get an idea about enzyme(s) catalysing the reaction. Practically all
major CYP enzymes have been expressed in various host cells, such as bacteria, yeast
and mammalian cells, and it is relatively straightforward to study either the
metabolism of, or inhibition by, a compound under study in a cell system expressing
a particular CYP enzyme.
It is possible to make a number of predictions on the basis of the known
characteristics of each CYP enzyme and on the basis of the known CYP-speci® city
of the metabolism of a compound. For example, if it is known that the CYP3A4
enzyme participates in the metabolism or interactions of a particular substance, it is
possible to identify some matters of concern on the basis of what is generally known
about CYP3A4. The following list of predictions is from the review articles of
Watkins (1994) and Wilkinson (1996) and some of these phenomena will be dealt
with more thoroughly in later sections.
E CYP3A4 is induced by rifampicin, antiepileptics, dexamethasone etc and
consequently, the elimination of the compound might be enhanced in situations
involving administration of these drugs.
E CYP3A4 levels are inhibited by ketoconazole, itraconazole and a large number of
other compounds, as well as by grapefruit juice. The metabolism of the
compound under study might be inhibited by these substances.
E CYP3A4 is activated by several ¯ avones and endogenous steroids. The ¯ avones,
which are constituents of food, may enhance the metabolism of substrates of
CYP3A4.
E CYP3A4 is very variable between individuals. Also, the elimination of the
studied compound may be variable.
E CYP3A4 is present in intestinal epithelium. This fact may lead to a ® rst-pass
eå ect with respect to the compound under study.
E CYP3A4 displays an age-related reduction in activity. The elimination of the
compound of interest may show the same phenomenon.
E CYP3A4 activity is decreased in liver cirrhosis. The elimination of the studied
compound is expected to be decreased in severe liver disease.
Probe drugs
The term ` probe drug ’ , also called ` marker drug ’ , was introduced into clinical
pharmacology during the 1970s when considerable interest arose on the in¯ uence of
environmental factors on drug-metabolizing enzyme activity. A probe drug is
devised to provide information, which allows for an extrapolation to other important
issues (enzyme activity, rate of metabolism of other compounds). There have been
attempts to envisage an ` ideal ’ probe drug, but obviously some of the more desirable
characteristics are that the probe drug is CYP-speci® c, safe to be used in vivo in man
and widely available, easily and reliably assayed in suitable body ¯ uids (including
P450 inhibition and induction in man 1209
Table 3. Probe or model drugs } substances claimed to be useful in vivo CYP identi® cation in man.
Probe substrate Methods availablea Enzymes*
Aminopyrine p } b, m(r) } ex, pm } u 1A, 3A, NAT2
Antipyrine p } b, p } s, pm } u 1A, 3A, (others)Caå eine pm } u 1A2, NAT2
Chlorzoxazone pm } b, pm } u 2E1,(1A2)Coumarin pm } u, (pm } b) 2A6
Dapsone pm } u NAT2Debrisoquine pm } u 2D6
Dextromethorphan pm } u 2D6, (3A4)Diazepam pm } b, pm } u, m(r) } ex 2C19, 2D6
Diclophenac pm } b 2C9Erythromycin m(r) } ex 3A4
Hexobarbital p } b, pm } u 2C19, (others)Lidocaine adm iv, pm } b 3A4, (1A2)
Lorazepam pm } u UGTMephenytoin pm } u 2C19
metronidazole p } b, pm } u nkMidazolam pm } b, pm } u 3A4
Nifedipine pm } b, pm } u 3A4Omeprazole pm } u 2C19
Paracetamol pm } u 2E1, 1A2, GST, GT,ST
Pentobarbital p } b nkPhenacetin p } b, m(r) } ex 1A2, 2E1
Phenytoin pm } b, pm } u 2C8 } 9Propranolol p } b, pm } u 2C19, 2D6
Sparteine pm } u 2D6Sulfamethazine pm } u NAT2
Theophylline p } b, pm } u 1A2Tolbutamide p } b, pm } u 2C9
Trimethadione p } b, pm } u 1A2, 3AWarfarin p } b, pm } u 2C9, 1A2, 3A4, 2C19
6 b -hydroxycortisol endogenous 3A4d -Glucaric acid endogenous nk
Modi® ed from Pelkonen and Breimer (1994), where original references can
be found.a p, Parent drug ; m, metabolite(s) ; b, blood (plasma, serum) ; u, urine ; s,
saliva ; (r), radioactive label ; ex, exhaled air ; adm iv, administered intra-venously ; nk, not known.
* NAT, N-acetyltransferase ; UGT, UDP-glucuronosyltransferase ; GST,glutathione S-transferase ; ST, sulphotransferase.
metabolites), and its pharmacokinetics is predominantly determined by metabolism
and not by liver blood ¯ ow or protein binding. In addition, the system should be
predictable, i.e. a limited number of samples should yield quantitative information
on the rate of metabolism and } or the rate of metabolite formation. Further
discussion on these aspects is found in a recent review by Kivisto$ and Kroemer
(1997).
A list of drugs (and some endogenous substances) which are claimed to be useful
as in vivo probe drugs for various purposes is given in table 3. Here some
information on CYP selectivity has been indicated, although we do not try to give
more detailed and quantitative information about this important characteristic of
any probe drug. Later on, we provide some detailed examples, including antipyrine,
a classical ` general ’ probe and warfarin. It would be of considerable importance to
analyse in a detailed and quantitative manner the applicability and usefulness of the
various proposed probe drugs.
1210 O. Pelkonen et al.
Inhibition : m echanism s and quantitation
The in-depth treatment and formal derivation of equations to characterise
various modes of inhibition can be found in appropriate textbooks and handbooks.
A good introduction to the basic phenomena of inhibition of drug metabolism is by
Boobis (1995). Here we will deal with only those aspects of inhibition that are
needed to understand the quantitative information given in subsequent tables.
Inhibitory potency in vitro
The most important single measure for inhibitory potency of a given compound
is the Ki, or inhibition constant, which expressed an aæ nity of a compound to an
enzyme. It should be stressed here that Ki
is characteristic for each particular
inhibitor and enzyme, and it is not dependent on any particular substrate used for
the quantitation of an enzyme. With respect to human hepatic P450 enzymes, this
value can be easily measured with standard in vitro approaches, in which various
concentrations of a substance are incubated with human liver microsomes and an
inhibition of a CYP-speci® c model reaction is quantitated. A substance may have
aæ nity for an enzyme without being metabolized by the same enzyme or it may be
an alternative substrate of the enzyme and serve as an inhibitor on this basis. In both
cases the Kiis derived from an in vitro experiment, but for an alternative substrate,
a Ki
should be the same as its Km
.
It may be worth stressing that assay conditions such as protein concentration,
buå er, ions, pH, and so on, may critically aå ect the inhibitory potency of the
compound (Ekins et al. 1998, Ma$ enpa$ a$ et al. 1998) and should be thoroughly
investigated.
Inhibition of clearance
For any substrate, the ratio Vmax
} Km
is a measure of intrinsic clearance, which
relates to the eæ cacy of an enzyme to metabolize a substrate. Usually, in clinical
usage, drug concentrations are far below their Km
, and in this situation it can be
demonstrated that the intrinsic clearance is decreased dependent on the ratio
between the concentration of an inhibitor to its Ki, [I ] } K
i. This statement is true for
whatever the mechanism of inhibition may be. In tables 4 and 5, and in some
subsequent tables, calculations based on this simple model have been performed :
assuming competitive inhibition and the substrate concentration far below its Km
(i.e. [S] ’ Km
), the percentage inhibition can be simply calculated according to the
equation I(I 1 Ki) 3 100. It has to be stressed that the number achieved is a very
crude ` ® rst guess ’ and depends on a number of other factors which will be discussed
below in some detail.
However, when substrate concentrations approach and exceed the Km
, the
mechanism of inhibition becomes important. In a competitive mode of inhibition,
increasing substrate concentration abolishes inhibition because the inhibitor is
increasingly removed from the active site of an enzyme. In this case, the denominator
of the above mentioned simple equation should contain the term (1 –[S] } Km
) ; the
higher the substrate concentration [S], the lower the percentage inhibition.
However, in a non-competitive mode of inhibition, a certain proportion of an
enzyme, which is determined by the ratio [I ] } Ki, is ` inactivated ’ for a more
P450 inhibition and induction in man 1211
Tab
le4
.S
ub
stra
tes
and
inh
ibit
ors
of
the
hu
man
CY
P1A
2en
zym
e.
Dru
gR
eact
ion
Km
or
Ki
(lm
)
[C]v
ivo"
(lm
)I
#
Inte
ract
ion
pote
nti
al
inviv
o$
Ref
eren
ces
Caå
ein
e3-d
emet
hyla
tio
n20
05
0(3
5)
25
1G
ran
tet
al.
(198
8),
Bu
tler
etal.
(19
89),
Tas
san
eey
aku
let
al.
(1993
)
In
h%:
fura
fyll
ine
0.1
10
(?)
99
1
Ola
nzap
ine
N-d
emeth
yla
tion
38
0.2
(?)
0.5
–R
ing
etal.
(199
6)
7-h
yd
roxy
lati
on
24
0.2
(?)
0.8
–R
ing
etal.
(199
6)
On
dan
setr
on
7,8
-hyd
roxy
lati
on
0.1
(70)
Ber
thou
etal.
(1993
)P
arace
tam
ol
oxid
ati
on
33
(20)
Pat
ten
etal.
(1993
)
Ph
enac
etin
O-d
eeth
yla
tion
39
??
?S
esar
dic
eta
l.(1
988
),B
rose
net
al.
(1993
)
In
h:
fura
fyll
ine
0.0
71
0(?
)99
(1
)S
esar
dic
eta
l.(1
990
)In
h:
¯u
voxam
ine
0.2
1(7
7)
83
(1
Bro
sen
etal.
(19
93
)
Pro
pra
no
lol
N-d
eiso
pro
py
lati
on
10
(1A
1)
1.2
(90)
11
–M
arat
he
eta
l.(1
99
4)
20
0(1
A2)
1.2
(90)
0.6
–M
arat
he
eta
l.(1
99
4)
Th
eop
hyll
ine
l-d
emet
hyla
tio
n42
010
0(6
0)
19
1R
ob
son
etal.
(19
87),
Ku
nze
eta
l.(1
99
3),
Gu
eta
l.(1
99
2),
Rasm
uss
enet
al.
(1994
),T
jia
etal.
(19
96)
3-d
emet
hyla
tio
n45
510
0(6
0)
18
18-h
yd
roxy
lati
on
55
010
0(6
0)
15
1
"M
axim
alco
ncen
trat
ion
of
the
dru
gin
viv
oaft
ercl
inic
ally
rele
van
td
ose
s.#
I=
inh
ibit
ion
perc
en
tage
:as
sum
ing
com
pet
itiv
ein
hib
itio
nan
dth
esu
bst
rate
con
cen
trat
ion
’K
m,
the
per
cen
tage
inh
ibit
ion
was
calc
ula
ted
acc
ord
ing
toth
e
eq
uat
ion
I }(I
1K
i)31
00
.$
Qu
alit
ativ
eev
iden
cefo
rin
viv
oin
tera
ctio
ns
cau
sed
by
the
dru
g.
%In
hib
itor
of
the
react
ion
ab
ove.
1212 O. Pelkonen et al.
Tab
le5
.S
ub
stra
tes
and
inh
ibit
ors
(In
h)
of
the
hu
man
CY
P2
C9
enzy
me
asas
sess
edin
hu
man
liv
erm
icro
som
es.
Dru
g}g
rou
pR
eact
ion
Km
or
Ki
(lm
)
[C]v
ivo"
(lm
)I#
Inte
ract
ion
po
ten
tial
inviv
o$
Ref
ere
nce
s
Dic
lofe
nac
4-h
yd
roxy
lati
on
41
0(9
9)
71
1L
eem
an
net
al.
(199
3),
Tra
nso
net
al.
(1996
)
S,R
-Ib
up
rofe
n2-h
yd
roxy
lati
on
38±47
10
(99)
25
1H
amm
anet
al.
(199
7)
In
h%:
sulf
aph
en
azo
leco
mp
etit
ive
inh
ibit
ion
0.1
1±0.1
28
0(6
5)
100
1H
amm
anet
al.
(199
7)
S,R
-ib
up
rofe
n3-h
yd
roxy
lati
on
21±29
10
40
1H
amm
anet
al.
(199
7)
In
h:
sulf
aph
enaz
ole
com
pet
itiv
ein
hib
itio
n0.0
6±0.0
78
0(6
5)
100
1H
amm
anet
al.
(199
7)
Nap
rox
enO
-dem
eth
yla
tio
n12
01
0(9
9)
8?
Rod
rigu
eset
al.
(199
6),
Tra
cyet
al.
(19
97)
In
h:
sulf
aph
enaz
ole
com
pet
itiv
ein
hib
itio
n1.6
80
(65)
100
1T
racy
etal.
(199
7)
In
h:
war
fari
nco
mp
etit
ive
inh
ibit
ion
27
10
(99)
27
?T
racy
etal.
(199
7)
In
h:
pir
oxic
amco
mp
etit
ive
inh
ibit
ion
23
20
(99)
47
?T
racy
etal.
(199
7)
In
h:
tolb
uta
mid
eco
mp
etit
ive
inh
ibit
ion
12
83
70
74
?T
racy
etal.
(199
7)
Ph
enyto
inR
-4´-
hy
dro
xyla
tion
50
80
(92)
62
1V
eron
ese
etal.
(19
91),
Bajp
ai
etal.
(1996
)
S-4
´-h
yd
roxyla
tio
n1
08
0(9
2)
89
1
Pir
oxic
am
5´-
hyd
roxy
lati
on
40
20
(99)
33
1L
eem
an
net
al.
(199
3)
Ten
oxic
am5´-
hyd
roxy
lati
on
40
20
(99)
33
1L
eem
an
net
al.
(199
3)
Tie
nil
icaci
d5´-
hyd
roxy
lati
on
63
3(9
9)
85
1L
op
ez
Gar
cia
eta
l.(1
99
3)
S-w
arfa
rin
7-h
yd
roxy
lati
on
41
0(9
9)
71
1R
etti
eet
al.
(199
2)
In
h:
sulf
aph
enaz
ole
com
pet
itiv
ein
hib
itio
n0.1
58
0(6
5)
100
1T
racy
etal.
(199
7)
"M
axim
alco
ncen
trat
ion
of
the
dru
gin
viv
oaft
ercl
inic
ally
rele
van
td
ose
s.#
I=
inh
ibit
ion
per
cen
tag
e:
assu
min
gcom
pet
itiv
ein
hib
itio
nan
dth
esu
bst
rate
con
cen
trat
ion
is’
Km
for
asu
bst
rate
,th
ep
ercen
tage
inh
ibit
ion
was
calc
ula
ted
acc
ord
ing
toth
eeq
uat
ion
I }(I
1K
i)31
00
.$
Qu
alit
ativ
eev
iden
cefo
rin
viv
oin
tera
ctio
ns
cau
sed
by
the
dru
g.
%In
hib
itor
of
the
react
ion
ab
ove.
P450 inhibition and induction in man 1213
prolonged period of time, being unavailable for catalysis, and the inhibition cannot
be abolished by increasing the substrate concentration.
Mechanism-based inhibition
For the P450 enzymes, the inhibitory species may not be the substrate but a
metabolite, which is then complexed or covalently bound to a metabolising enzyme
itself (` suicide inhibition ’ ) or to other enzymes nearby. The consequence is a
removal of a variable proportion of an enzyme from active catalysis, i.e. a non-
competitive mode of inhibition. However, the detection of mechanism-based
inhibition requires speci® c incubation conditions. A preincubation of liver micro-
somes in the presence of an inhibitor under the metabolising conditions is necessary,
because the presence of a substrate might competitively inhibit the metabolism of a
mechanism-based inhibitor.
A speci® c case of mechanism-based inhibition is the situation in which an
enzyme is inactivated very slowly during in vivo conditions. In this case it is diæ cult
to reveal inhibition in in vitro experiments.
Concentration of the inhibitor
Whatever the exact Kiis, it does not directly tell us inhibition will be observed
during the in vivo use of a compound. The critical factor in the term [I ] } Ki
is the
concentration of an inhibitor, which ideally means the concentration at the active
site or a modulatory site. Obviously, this particular concentration is not known and
surrogate values are usually used, such as total or free concentration in the plasma.
Most authors think that the unbound (i.e. free concentration) is the most appropriate
to use, because it is only free drug that is able to transfer to hepatocytes and to the
vicinity of P450 enzymes. However, it is conceivableÐ and for some drugs even
shownÐ that many lipid-soluble drugs are concentrated in hepatocytes and
consequently the actual concentration in the liver far exceeds that in plasma. Even
the measurement of the partition between liver and plasma does not necessarily
indicate the available portion of a drug to an enzyme, because a drug may be very
tightly bound inside hepatocytes and may not be available to the active site of the
enzyme. A detailed and extensive treatment of modelling and predicting interactions
of drug metabolism, including factors aå ecting partition between liver and plasma,
can be found in Leemann and Dayer (1995). In the current review, we have used
plasma concentrations as such, taken mostly from general sources (Dollery et al.
1991, Hardman et al. 1996), but we have also tabulated plasma protein binding of the
drugs, so that the interested reader could calculate the theoretical inhibition
percentages by the ` free ’ drug. Diå erent sources give slightly diå erent plasma
concentrations, but we have usually selected the highest therapeutic concentration,
if known.
Clinical signi® cance of an interaction
Aæ nity and CYP speci® city can be studied in vitro and thus a potential of a drug
to cause interactions can be revealed. However, this does not yet mean that the
compound would cause clinically signi® cant interactions. For such interactions to
occur, two prerequisites have to be ful® lled :
1214 O. Pelkonen et al.
E The concentration of the drug in clinical situation should be high enough, so that
inhibition would be manifested in vivo.
E The therapeutic index of the drug should be narrow, such that a change caused
by an interacting drug would cause side eå ects.
The clinical signi® cance of a drug interaction involves also a judgmental
component, which in most cases is rather large. The judgmental components
involve the severity of potential harm to the patient, assessment of decreased
therapeutic outcome and so on. This makes it diæ cult to say unequivocally whether
an interaction is ` clinically signi® cant ’ . Semiquantitative classi® cations have been
constructed, such as that of Preskorn (1993) using the terms ` substantial ’ ,
` moderate ’ , ` mild ’ , ` unlikely ’ , ` not clinically signi® cant ’ . However, in the end
clinical assessment and judgment is the ® nal arbiter as to the clinical and therapeutic
signi® cance of an interaction and this assessment may be diæ cult to put into exact
numbers and may cause disagreement even between experts.
Exam ples of substrates and inhibitors with aæ nity predom inantly to a
single CYP enzym e
In the following sections we make an attempt towards semiquantitative
assessment of the inhibitory potential of some substrates and inhibitors with
variable speci® cities towards CYP forms. The Km
and Ki
are taken from the
appropriate in vitro studies. Evidently there is some variation in the exact numbers
taken from studies performed in various laboratories. In this treatment, we do not
usually present Vmax
and clearances, although they would allow for calculation of the
extent to which the metabolism of a compound is aå ected by various inhibitors.
Clearances for individual CYPs are especially important for substrates which are
metabolized signi® cantly via several more or less equally important enzymes.
However, usually it is rather diæ cult to decide the approximate proportion of the
total clearance that is due to a particular CYP enzyme. In terms of potential
signi® cant interactions, the often cited view is that the inhibition of the clearance has
to be " 50 % for the interaction to be ` clinically signi® cant ’ . However, any exact
limit is debatable, because ` clinically signi® cant interaction ’ is strongly dependent
on the narrowness of the therapeutic to toxic dose levels and on the generality or
speci® city of the target site of toxicity.
Calculations for inhibitory potencies are based on the simple equation presented
above. These calculations can certainly be re® ned by taking into consideration some
additional factors in the models, such as plasma protein binding, absorptive phase
concentrations in the portal blood, partition of a drug between liver and plasma,
organelle accumulation in the hepatocyte and so on. The problem is that we do not
usually know many of those factors. We have also collected some data on
metabolism-related interactions of the compounds tabulated. These data are taken
mainly from textbooks, handbooks or desk reference sources (Dollery et al. 1991,
Hardman et al. 1996) and are presented in a simplistic way. Nevertheless, we hope
that some conclusions can be made from these data.
CYP1A2
In man, the CYP1A1 protein is expressed at a very low level in the liver (Wrighton
et al. 1986), whereas CYP1A1 and its associated activities can be detected and are
inducible by cigarette smoke and PAHs in extrahepatic tissues like the lung and
P450 inhibition and induction in man 1215
placenta (Pasanen and Pelkonen 1994, Raunio et al. 1995). Although CYP1A1 is able
to oxidize a number of drug substrates (as has been demonstrated with, e.g.,
heterologously expressed CYP1A1), we will not deal with this enzyme further in this
review.
The CYP1A2 gene product is clearly the predominant hepatic enzyme of
CYP1A subfamily in man, although it is quite variably expressed in human liver
(Shimada et al. 1994). There is no evidence of signi® cant expression of CYP1A2 in
extrahepatic tissues.
Substrates and inhibitors. Some examples of substrates and inhibitors for CYP1A2
are shown in table 4. The puri® ed human CYP1A2 protein was originally shown to
catalyse phenacetin O-deethylation (Distlerath et al. 1985). Caå eine has been used
as an in vivo metabolic probe for CYP1A2 (Butler et al. 1989). Fast and slow
metabolisers of caå eine 3-demethylation have been identi® ed, although the genetic
basis for this distinction is not clear (Butler et al. 1992). Also theophylline has been
reported to be a speci® c substrate for this enzyme in man (Robson et al. 1987) and
concurrent treatment with theofylline and inhibitors of CYP1A2 may lead to
harmful drug interactions (Stockley 1996). Both xanthines are rather interesting in
that their Km
for CYP1A2 are very high (hundreds of l m ), but they have also very
high plasma concentrations, making it probable that they might cause interactions
with other drugs metabolized via CYP1A2 (table 4).
a -Naphtho¯ avone (7,8-benzo¯ avone) has been shown to be a potent and
relatively speci® c inhibitor of both CYP1A isoforms (Burke et al. 1977). However,
it has not been used in vivo in man. Furafylline, a methylxanthine analogue, is a
potent inhibitor of several CYP1A2-associated metabolic reactions (tables 2 and 4),
whereas it has only a weak eå ect on CYP1A1 (Sesardic et al. 1990). However,
furafylline is not available for in vivo use because it causes severe interactions with
caå eine (Tarrus et al. 1987). A selective serotonin reuptake inhibitor, ¯ uvoxamine
has also been reported to be a potent inhibitor of CYP1A2, as exempli® ed by the
inhibition of phenacetin O-deethylation and theofylline metabolism (Brosen et al.
1993, Rasmussen et al. 1995). However, it seems not to be as speci® c as furafylline.
More information on ¯ uvoxamine will be presented in a later section.
CYP2C9
The human genome has been shown to contain several genes belonging to the
CYP2C subfamily (Goldstein and de Morais 1994) and they have been shown to be
expressed at signi® cant levels only in the liver. The metabolic roles of the diå erent
hepatic enzymes in this subfamily are still rather poorly de® ned and here we deal
only with CYP2C9 and CYP2C19 in some detail. Nevertheless, CYP2C8 has been
puri® ed from human liver in diå erent laboratories (Wrighton et al. 1987, Ged et al.
1988, Leo et al. 1989). It has a role in the metabolism of endogenous substances like
retinol and retinoic acid and drugs such as benzphetamine (Wrighton et al. 1987,
Leo et al. 1989). Tolbutamide is also metabolized by CYP2C8, although the aæ nity
of tolbutamide for this isoform is clearly lower than for CYP2C9 (Relling et al. 1990,
Veronese et al. 1993).
Substrates and inhibitors of CYP2C9. A number of important drugs are substrates
of CYP2C9 (table 5). CYP2C9 participates in the hydroxylation of tolbutamide and
1216 O. Pelkonen et al.
hexobarbital (Shimada et al. 1986, Brain et al. 1989) as well as phenytoin and
warfarin (Veronese et al. 1991, Rettie et al. 1992). Currently it seems that diclofenac
4-hydroxylation is becoming a useful probe drug for both in vitro and in vivo studies
(table 2). A lot of in vitro information has been published on ibuprofen and naproxen
(table 5). Both substrates are stereoselectively metabolized by CYP2C9, and this has
been demonstrated also with a recombinant enzyme (Hamman et al. 1997, Tracy et
al. 1997). The Km
for ibuprofen is about 20± 50 l m and that for naproxen about
120 l m (a high-aæ nity ® gure), but when compared with their in vivo concentrations
they are similar enough to expect signi® cant interactions. However, when one takes
into consideration an extensive plasma protein binding, the calculated in vivo
inhibition percentages remain rather small. This same phenomenon seems to be true
with respect to most anti-in¯ ammatory (and other) drugs listed in table 5.
Nevertheless, at least some interactions based on metabolism have been reported in
monographs dealing with these compounds. Obviously we need much more
information about the eå ect of plasma protein binding on hepatic uptake and
accumulation.
Sulphaphenazole is a potent and speci® c inhibitor of the CYP2C9 enzyme and it
appears to inhibit the metabolism of various NSAIDs as well as tolbutamide with
a roughly similar potency (table 5) (Brian et al. 1989, Veronese et al. 1993).
Sulphaphenazole is also an eå ective in vivo inhibitor (Birkett et al. 1993).
CYP2C9 and other CYPs in warfarin metabolism. Warfarin, a coumarin-type
anticoagulant, is extensively oxidized in human and rodent liver microsomes,
principally by P450-mediated reactions (Kaminsky 1989, Rettie et al. 1989). The R-
and S-enantiomers of warfarin are metabolized by diå erent metabolic pathways.
S-warfarin is mainly metabolized to 6- and 7-hydroxywarfarin. Small amounts of
other hydroxy metabolites and warfarin alcohol are also formed. R-warfarin is
oxidized presumably by P450 enzymes to 6-, 7-, 8-, and 10-hydroxywarfarin, but
the main metabolic pathway is reduction by soluble enzymes to warfarin alcohol
(Kaminsky and Zhang 1997).
The warfarin alcohols and hydroxy metabolites are excreted in the urine and in
bile, and also enterohepatic circulation occurs. Of the dose, 85 % may be recovered
as metabolites in urine with ! 1 % as the unchanged drug. The mean plasma half-
life of warfarin is about 36 h, with a relatively wide variation from 10 to 45 h.
However, the S-enantiomer has a shorter half-life of 18± 35 compared with 20± 60 h
for the R-enantiomer. Total plasma warfarin clearance ranges from 2.5 to
6.4 ml 3 h Õ " 3 kg Õ " . Therapeutic plasma concentrations at steady state range from
300 l g } l to 3 mg } l with a wide interindividual variation. Warfarin is highly albumin
bound with values ranging from 97 to 99.5 % (Dollery et al. 1991).
In vitro studies with human liver microsomes have demonstrated the predictive
value of a simple inhibition screening with warfarin as an inhibitor. The inhibitory
eå ect of racemic warfarin on CYP model activities have indicated that warfarin
inhibited CYP2C9-catalysed tolbutamide methylhydroxylation with a Ki
of about
6± 12 l m . Values for other CYPs were at least 30± 40 times higher (unpublished data).
This simple experiment demonstrates the predominant a æ nity of warfarin towards
CYP2C9, suggesting a need for more thorough studies. The Kifor the inhibition of
tolbutamide methylhydroxylation (6± 12 l m ), indicates a relatively high aæ nity and
if this aæ nity is associated also with metabolism of warfarin it might indicate an
enzyme that is metabolizing warfarin at therapeutic concentrations of 2 mg } l
P450 inhibition and induction in man 1217
Table 6. Kinetics of oxidative metabolism of warfarin by human liver microsomes and recombinant
expressed CYP enzymes.
CYP " Metabolite Km
( l m )
Vmax
(nmol } mg 3 h)
Formationclearance
in vivo #
S-warfarin M 7OH 4 0.5 1847M 6OH 3 0.1 400
300 1.1
r2C9 7OH 4 (40) $
r2C9 60H 4 (7)
r3A4 6OH 300 (90)
R-warfarin M 6OH 265, 1412 0.9, 11.6 462M 7OH 159, 1580 0.3, 2.7 227
M 8OH 162, 1500 0.9, 2.2 338M 10OH 400 2.4 342
r1A2 6OH, 7OH, 1600 not available
8OHr2C19 8OH, 6OH, C 200 not available
7OHr3A4 10OH 400 (200)
Data derived from Kunze and Trager (1996) and Kunze et al. (1996)." M, human liver microsomes ; r, recombinant.# ml 3 h Õ " 3 kg Õ " 10 Õ $ , from Black et al. (1996).$ Figures in parentheses mean activity in pmol } mg protein 3 min.
(10 l m ). Quantitative prediction is possible only when the kinetic parameters for
warfarin metabolism have been determined. Inhibition screening does not give this
information. However, by using an in vitro inhibition screening study it is possible
to pinpoint a high-aæ nity CYP form for warfarin. Even if CYP2C9 is not a
metabolizing enzyme, the high aæ nity would indicate a possibility for interactions.
Warfarin metabolism in human liver microsomes has been studied with
diagnostic inhibitors and antibodies and correlation analysis, as well as with
recombinant enzymes. With all of these approaches, the identity of enzyme(s)
catalysing various oxidative pathways of warfarin metabolism as well as the kinetic
parameters have convincingly been demonstrated (table 6 ; Kunze et al. 1996). On
the basis of comparison of Km
for the formation of various warfarin metabolites it
can be anticipated that (S)-7- (and 6-) hydroxymetabolite is (are) predominantly
formed at clinically achievable warfarin concentrations and the predominant
catalysing enzyme is CYP2C9. With respect to R-warfarin clearance, at least three
CYPs participate, but the Km
are almost two orders of magnitude higher than that
for CYP2C9 (table 6).
The formation clearances for each of the metabolites formed from the (R)- and
(S)-warfarin in human subjects have been recently determined (Black et al. 1996).
Comparison of the above in vitro data with metabolite formation clearances in vivo
seem to show a relatively direct correspondence (table 6). The formation clearances
of (S)-6- and (S)-7-hydroxywarfarin represent up to 90 % of the total metabolite
clearance of S-warfarin, a ® gure that is in an excellent correlation with the role of
CYP2C9 in the in vitro metabolism of S-warfarin.
Because CYP2C9 is such a predominant catalyst of S-warfarin clearance,
clinically signi® cant interactions (inhibition and induction) could have been
predicted on this basis (see above, and also a later section on induction). Several
P450 enzymes, including at least CYP1A2, CYP2C19 and CYP3A4, catalyse the
1218 O. Pelkonen et al.
formation of (R)-hydroxywarfarins (table 6). Also on the basis of in vivo ® ndings
with inducers and inhibitors of the P450 system, the participation of the above
mentioned CYPs can be at least tentatively identi® ed.
On the basis of the above ® ndings it can be concluded that the most important
warfarin-oxidising enzyme, CYP2C9, has been identi® ed by in vitro approaches.
Because the Km
for other P450 forms are at least 40± 50 times larger, it can be
concluded that their contribution to the overall metabolism of warfarin must be
small, if substantial CYP2C9 activity is present. The knowledge of general
properties of CYP2C9 would also have enabled at least qualitative, if not
quantitative, predictions to be made about the pharmacokinetic behaviour and
potentially signi® cant inhibition and induction interactions of warfarin.
It has been repeatedly suggested on the basis of in vitro studies, that warfarin
would seem to be a promising probe compound for in vivo studies. However, it has
been used only to a very limited extent. One of the reasons for this is that as an
anticoagulant warfarin has potentially hazardous side eå ects, although the use of a
single, smaller-than-therapeutic dose may not manifest prolongation of bleeding
time. Another potential problem in the use of warfarin as a probe drug is its high
degree of protein binding. Furthermore, a complicating factor with warfarin is the
stereochemical selectivity in its metabolism which requires stereoselective analysis
of parent enantiomers and metabolites (Lam 1988). Currently it can only be said that
the formation rate of the 7-hydroxymetabolite of S-warfarin could be used as an
index of the CYP2C9 activity in vivo, but the usefulness of other metabolites as
indices for other CYPs remains to be demonstrated.
CYP2C19
CYP2C19-mediated 4´-hydroxylation of S-mephenytoin is polymorphically
expressed in humans and recent studies have demonstrated that the polymorphism
is due to at least two major and several minor variant alleles of CYP2C19 (Goldstein
and de Morais 1994). The PM phenotype based on two major variant alleles is rather
infrequent among Caucasians (2± 4 %), but is much more common in Orientals
(around 20 %) (Wedlund et al. 1984, Alvan et al. 1990).
Substrates and inhibitors. There are a number of substrates for the CYP2C19
enzyme, but very few even remotely speci® c inhibitors (Guengerich 1995b).
Proguanil, omeprazole and imipramine are metabolized by CYP2C19, but also
other CYPs are important catalysts of the metabolism of these drugs (Andersson et
al. 1993, Birkett et al. 1994). Omeprazole may be the most promising probe for in
vivo studies and the search for speci® c inhibitors continues. Recently, ¯ uconazole
and ¯ uvoxamine have been shown as potent inhibitors of CYP2C19-mediated R-
warfarin 8-hydroxylation in vitro (Kunze et al. 1996) and CYP2C19-mediated
proguanil bioactivation in vivo (Jeppesen et al. 1997), respectively, but both
compounds seem rather unspeci® c.
CYP2D6
Individuals can be classi® ed into extensive (EM) and poor metabolizers (PM)
according to their genetically determined ability (phenotype) to oxidize a number of
drugs, such as debrisoquine, sparteine, bufuralol and dextromethorphan (Mahgoub
P450 inhibition and induction in man 1219
et al. 1977, Eichelbaum et al. 1979). The molecular basis of this polymorphism
(called CYP2D6 polymorphism) has been elucidated in great detail (Meyer et al.
1990). About 7 % of the Caucasian population are PMs (Alvan et al. 1990), because
mutations in CYP2D6 gene have led to an absence of a functional CYP2D6 protein
(Gonzalez 1990, Meyer 1994). Also individuals carrying multiple copies (i.e. the
ampli® cation) of the active CYP2D6 gene have been detected (Johansson et al.
1993). It is remarkable that the CYP2D6 enzyme seems to be resistant to xenobiotic
induction, which aå ects the activities of other P450 enzymes. The only clear
example of an exogenous in¯ uence is the competitive inhibition of the enzyme by a
number of drugs, including quinidine and some neuroleptics (Brosen and Gram
1989). Thus, the study of environmental in¯ uences on CYP2D6 is of interest, but
mainly because of the possible interference upon the phenotyping of the trait and
clinically important drug interactions.
Substrates and inhibitors of CYP2D6. The importance of CYP2D6 polymorphism
is substantial, since numerous drugs, including cardiovascular drugs, b -adrenergic
blocking agents (bufuralol, metoprolol and propranolol), tricyclic antidepressants
(amitriptyline, nortriptyline and imipramine), neuroleptics (perphenazine, thio-
ridazine, haloperidol and clozapine) and miscellaneous other drugs like codeine,
dextromethorphan and phenformin are substrates for CYP2D6 (Cholerton et al.
1992). It is important to know which substances interact with CYP2D6, since many
of the therapeutic drugs listed above have a narrow therapeutic window. conse-
quently, dangerous drug interactions may occur when using drugs that are oxidized
by CYP2D6.
The inhibitor spectrum of CYP2D6 has been thoroughly studied. Quinidine
is a highly selective and potent inhibitor, although it is not a substrate of the
CYP2D6 enzyme (Guengerich et al. 1986) (table 2). In a survey of diå erent
chemicals on their eå ects on bufuralol 1-hydroxylase, an activity speci® c for
CYP2D6, several alkaloids and neuroleptics were found to be potent inhibitors
(Fonne-P® ster and Meyer 1988). The Ki
of the alkaloid ajmalicine was as low as
3.3 n m . Many of a new class of antidepressant drugs, selective serotonin reuptake
inhibitors or SSRIs are substrates for CYP2D6 and } or inhibit it (Brosen 1993) as we
describe in a later section.
CYP2E1
Only one gene belonging to this subfamily has been identi® ed in the human
genome, namely CYP2E1 (Ronis et al. 1996). The activity of CYP2E1 is aå ected by
numerous factors, including alcohol drinking, several drugs such as isoniazid and
some pathophysiological conditions such as diabetes, ketonemia and obesity (Koop
1992, Ronis et al. 1996). The inducing eå ect of ethanol on CYP2E1 is discussed in
a later section. It seems probable that CYP2E1 is expressed and induced also in some
extrahepatic tissues, but the signi® cance of extrahepatic activity in the kinetics of
drugs in vivo is not clear (Shimizu et al. 1990). Since the rodent and human CYP2E1
enzymes catalyze similar reactions, rat and mouse are good models when screening
for substrates of this enzyme.
Substrates and inhibitors of CYP2E1. Over 60 substrates have been shown to be
metabolized by this enzyme (Koop 1992). Most substrates are carcinogens or other
1220 O. Pelkonen et al.
toxicants and there are only a few drug substrates. Because of the proposed relatively
small substrate pocket of the enzyme, CYP2E1 accepts various volatile anaesthetic
agents as substrates (Koop 1992). Chlorzoxazone has become a widely used substrate
for CYP2E1 in vitro (table 2). The advantage of using this compound is that the
chlorzoxazone 6-hydroxylase assay is very sensitive compared with the former
CYP2E1-speci® c assays used. Chlorzoxazone might also be an appropriate probe to
study CYP2E1 function in vivo in man and its role in pathogenesis of diå erent
diseases like alcoholism and diabetes (Kim et al. 1995). However, recent studies
indicate that CYP1A1 is also able to metabolize chlorzoxazone (Ono et al. 1995).
Because CYP1A1 may be a prominent enzyme in extrahepatic tissues especially after
PAH-type induction, chlorzoxazone may not be used as a speci® c probe for CYP2E1
in extrahepatic tissues.
There are several more or less speci® c inhibitors of CYP2E1. Disul® ram inhibits
CYP2E1-associated activities in man (Guengerich et al. 1991). Disul® ram is
reduced to diethyldithiocarbamate which inhibits CYP2E1 relatively potently, but
it is also an almost equally potent inhibitor of CYP2A6 (Brady et al. 1991,
Guengerich et al. 1991). Also 3-amino-1,2,4-triazole, phenethyl isothiocyanate and
dihydrocapsaicin are speci® c mechanism-based inhibitors of CYP2E1 in rodents
(Koop 1992).
It should be stressed that ethanol and acetone, as well as several volatile
anaesthetics, all substrates for CYP2E1, can attain relatively high levels in the
body and might thus interfere with CYP2E1-catalysed reactions. In experimental
conditions, many organic solvents that are widely used as vehicles of compounds to
be studied in in vitro incubations with tissue preparations, are relatively potent
inhibitors of CYP2E1 and could give completely erroneous results if not properly
used.
Human CYP3A subfamily
The members of the CYP3A subfamily are CYP3A4, CYP3A5 and CYP3A7.
These enzymes have a central role in drug metabolism since they are the most
abundant forms of P450 (20± 60 %) in human liver (Guengerich 1995b). In addition,
CYP3A4 is expressed in the human intestine and it catalyses drug metabolism there
as well (Kolars et al. 1992b, Guengerich 1995b). CYP3A4 is expressed in all human
livers and about 50 % of drugs currently in the market are substrates for it. The
CYP3A5 protein is expressed at detectable levels in the human liver in about 25 %
of individuals. The third member of the CYP3A subfamily is CYP3A7 that is
particularly expressed in human foetal liver (Wrighton and Stevens 1992). A
number of structurally diå erent compounds are substrates for these isoforms
including steroids, macrolide antibiotics, benzodiazepines and other miscellanous
substances (Wrighton and Stevens 1992).
Substrates and inhibitors. It seems that all the members of CYP3A subfamily have
similar substrate preferences (Gonzalez 1992b, Guengerich 1995b). However,
CYP3A5 may have some diå erences in its aæ nity to bind substrates when compared
with CYP3A4 (Wrighton et al. 1989, 1990). cDNAs expressing CYP3A4 and
CYP3A4 eå ectively catalyse the oxidation of testosterone, progesterone and
androstenedione, which may be physiologically important reactions (Waxman et al.
1991). CYP3A enzymes metabolise many drugs including cortisol, quinidine,
nifedipine, diltiazem, lidocaine, lovastatin, erythromycin, troleandomycin, cyclo-
P450 inhibition and induction in man 1221
sporin, warfarin, triazolam and midazolam (Guengerich and Shimada 1991,
Wrighton and Stevens 1992). many procarcinogens like AFB1 are also activated by
CYP3A enzymes (Aoyama et al. 1990, Guengerich 1993). In conclusion, the CYP3A
subfamily is very important in catalysing the metabolism of diå erent drugs,
carcinogens and endogenous substances.
In recent years diå erent diagnostic in vivo probes measuring CYP3A activity
have been developed. The ® rst described in vivo system was the non-invasive
method of Saenger et al. (1981) to measure the amount of 6 b -hydroxycortisol in
urine. Erythromycin N-demethylase activity can be measured by the 14[C]-
erythromycin breath test (Watkins et al. 1989). Other in vivo probes of CYP3A4
tested include midazolam, nifedipine, dapsone and lidocaine (Watkins 1994).
Midazolam is a well characterised probe for CYP3A4 (see below). However,
correlations between diå erent in vivo CYP3A probes in man are not always very
good and may arise from the heterogeneity of CYP3A isoforms. It is not always
clear which CYP3A isoform is responsible for the metabolism of a drug in question.
There is a number of isoform-speci® c inhibitors of the members of CYP3A
subfamily. Troleandomycin (TAO) has been shown to form a metabolic-inter-
mediate complex with CYP3A isoforms (Pessayre et al. 1983) and seems to be
relatively selective. Gestodene is also a selective mechanism-based inhibitor of
CYP3A4 and CYP3A5 (Guengerich 1990, Wrighton et al. 1990). These inhibitors
have to be initially oxidized before they form complexes with speci® c P450s. Also,
many substrates listed above inhibit CYP3A mediated reactions.
Grapefruit juice has been shown to inhibit the metabolism of a number of
CYP3A substrates (Bailey et al. 1991, Soons et al. 1991). The components of
grapefruit juice, like ¯ avonoids and furanocoumarins have been claimed to inhibit
CYP3A enzymes, and further the metabolism of CYP3a substrates like felodipine,
cyclosporine, terfenadine and midazolam just a few to mention (Ameer and
Weintraub 1997). However, it was recently shown by Lown et al. (1997) that the
inhibition of the metabolism of CYP3A substrates by grapefruit juice may be due to
reduction of the CYP3A4 protein in small intestine and not to the inhibitory role on
CYP3A4 of ¯ avones found in grapefruit juice (Guengerich 1995b).
An interesting feature of CYP3A4 is that it has been shown to be stimulated by
various substances like ¯ avones (Guengerich 1995b). Further, autostimulation by
the substrate itself has been shown to occur with several substrates (Ekins et al.
1998). The stimulators have to be keep apart from inducers, which increase the
protein expression in the cell. The mechanism may vary depending on the stimulator
in question. The stimulation of the enzyme may occur when the substrate or
stimulator binds to an allosteric site of the enzyme leading to a conformational
change of the enzyme (Ekins et al. 1998). It has also been suggested that the
stimulation may occur by enhancing the interaction of NADPH-P450 reductase
with CYP3A4 or the stimulator and the substrate bind simultaneously to diå erent
sites in the active centre of CYP3A4 (Guengerich 1995, Ekins et al. 1998). Recently,
Koley et al. (1997) suggested that the stimulator may activate an inactive
subpopulation of CYP3A4. The most potent stimulator of CYP3A4 catalytic
activity known is a -naphtho¯ avone, although many other ¯ avones also stimulate
this activity (Shou et al. 1994). Flavonoids are widespread in natural foods (Yang
et al. 1992) and therefore the stimulation of CYP3A4 activity may have clinical
signi® cance. Further, endogenous substances like progesterone and testosterone
have also been shown to stimulate CYP3A-mediated reactions (Johnson et al. 1988,
1222 O. Pelkonen et al.
Kerr et al. 1994, Ma$ enpa$ a$ et al. 1998). However, the clinical signi® cance of these
® ndings is unclear, but potentially the stimulation of CYP3A may result in low
plasma levels of CYP3A substrates or the stimulators may enhance the activation of
carcinogens by CYP3A. The stimulation of midazolam metabolism is discussed
below.
CYP3A enzymes are induced by several antiepileptics, rifampicin and cortico-
steroids which may lead to many clinically signi® cant drug interactions as discussed
in detail later.
CYP3A4 and inhibition of cyclosporin oxidation. Pichard et al. (1990) have
published a very extensive paper where they studied the inhibition of cyclosporin
metabolism by a large number of potential CYP3A4 substrates and inhibitors in
isolated human hepatocytes. The compounds studied, as well as some additional
information, are listed in table 7. Several important conclusions can be made on the
basis of this information.
E It seems that apparently there is very little correlation between the percentage
inhibition, calculated on the basis of a Ki
and in vivo plasma concentration, and
the potential of a compound to cause interactions that are regarded as ` clinically
signi® cant ’ .
E If plasma protein binding is taken into consideration in the calculations (i.e. free
concentrations are used), even smaller percentage inhibition would be obtained
and the discrepancy between the calculated inhibition and the expectation of
` clinically signi® cant ’ interactions becomes even more noticeable.
E Some substances, especially cimetidine and erythromycin, are clearly more prone
to cause in vivo interactions than would be predicted on the basis of in vitro
studies (Ki) and in vivo achievable concentrations. For these compounds the
obvious reason is their conversion to reactive products which cause mechanism
based inhibition. How much ` suicide inhibition ’ would explain other dis-
crepancies (e.g. see bromocriptine) remains to be evaluated. Another possibility
is that the drug is converted into a metabolite or metabolites, which is (are) the
predominant species in the body and which cause potential interactions.
At the present moment, the reasons for poor correlations are unclear. However, the
secondary sources from where we extracted the information on potential inter-
actions, may list some interactions on the basis of what is expected from the
knowledge that two compounds are metabolized by the same enzymes, and not on
the basis of actual positive studies. It remains to be seen whether a detailed, more
quantitative analysis would yield a better correlation between in vitro predictions
and actual in vivo changes (table 7).
Drug interactions with midazolam, a probe drug for CYP3A enzymes. Midazolam is
a short-acting benzodiazepine derivative that has been used as a hypnotic agent
(Dundee et al. 1984). The metabolic pathways of midazolam have been identi® ed
both in vitro and in vivo (Guengerich 1995b). Further, interactions between
midazolam and many other commonly used drugs have been thoroughly studied
both in vitro and in vivo. Therefore we chose midazolam as an example to discuss the
advantages and problems found when analysing in vitro studies to predict drug
interactions in vivo. It is also evident that CYP3A4 is a unique P450 enzyme because
of its complex properties that make the in vitro± in vivo correlations diæ cult to judge.
P450 inhibition and induction in man 1223
Table 7. Inhibition aæ nity of drugs for CYP3A4, as measured by inhibition of the oxidative CYP3A4-
mediated metabolism of cyclosporin in human cultured hepatocytes, and comparison with in vivoobserved interactions (inhibition potency data taken from Pichard et al. 1990).
Inhibitor Ki
( l m )C ( l m ) #
in vivo
Calculated
inhibition(%) "
Interactionpotential #
Clotrimazole 0.1 2.5 96 ?
Ketoconazole 0.7 10 (98) 93.5 1Miconazole 0.9 2.5 (92) 73.5 1Itraconazole 1.2 0.4 (99) 25 1Nicardipine 8 0.3 (95) 3.6 1Bromocriptine 8 0.001 (96) 0.01 1Troleandomycin 10 3 23 1Nifedipine 10 0.3 (90) 3.0 1Terfenadine 10 0.01 0.1 ?
Ergotamine 12 ? ? ?Isradipine 12 0.15 (96) 1.2 1Josamycin 19 3 14 1Midecamycin 22 3 12 1Dihydroergotamine 23 ? ? ?Verapamil 24 1.5 (90) 6 1Midazolam 40 0.25 (96) 0.6 –Progesterone 45 0.04 (97) 0.1 ?
Fluconazole 60 70 54 1Diltiazem 63 0.3 (85) 0.5 1Erythromycin 75 3 (83) 4 1Glibenclamide 78 0.1 (99) 0.1 ?
Cortisol 125 0.6 (95) 0.5 1Ethinylestradiol 172 0.5 (95) 0.3 ?
Prednisone 190 0.7 (80) 0.4 1Me-prednisone 190 0.7 (80) 0.4 1Prednisolone 210 0.7 (80) 0.3 1
" Assuming competitive inhibition and the substrate concentration ’ Km
for cyclosporin metabolism, the percentage inhibition was calculated accordingto the equation I(I 1 K
i) 3 100.
# Data on in vivo maximal concentrations, extent of plasma protein binding(in parentheses) and interaction potential have been collected mainly from
monographs and handbooks (Dollery et al. 1991, Hardman et al. 1996). Plus-sign means that clinical studies have indicated interactions between the
inhibitor and the CYP3A4-mediated elimination and } or metabolite formationof cyclosporin or other CYP3A4-associated drugs.
In vitro metabolism. Midazolam is metabolized to 1´-hydroxy (1´-hydroxy-
midazolam) and 4-hydroxy midazolam (4-hydroxymidazolam) in vitro by human
liver microsomes (Kronbach et al. 1989, Gorski et al. 1994). The in vitro metabolism
of midazolam is catalysed solely by CYP3A enzymes. Human CYP3A4 and
CYP3A5 enzymes have been shown to have similar substrate preferences (see above)
and 1´-hydroxymidazolam and 4-hydroxymidazolam formation are catalyzed by
both CYP3A4 and CYP3A5 isoforms (Kronbach et al. 1989, Gorski et al. 1994).
However, it has been reported that microsomal samples containing high levels of
CYP3A5 had a higher 1´-hydroxymidazolam } 4-hydroxymidazolam ratio than the
samples containing only CYP3A4 (Ma$ enpa$ a$ et al. 1998). In addition, CYP3A7 is
responsible for 1´-hydroxymidazolam and 4-hydroxymidazolam formation in
human foetal liver microsomes (Gorski et al. 1994 ; Ma$ enpa$ a$ et al. 1998).
In vivo metabolism . Midazolam is also metabolised to 1´-hydroxymidazolam and 4-
hydroxymidazolam in vivo. Both metabolites are pharmacologically active and both
1224 O. Pelkonen et al.
Table 8. Eå ect of several inhibitors and inducers of CYP3A4 on 1´-hydroxymidazolam formation in
vitro and on midazolam AUC( ! ± ¢ in vivo in human volunteers.
Inhibitor or inducer*IC
& !or K
i( l m )
AUC, % of control(placebo)
Erythromycin 194** 442
Azithromycin 170 87Verapamil 100 292
Fluconazole " 80** 373Itraconazole 1 1080
Ketoconazole 0.1* 1590Rifampicin* inducer 4
Data are derived from the following : Gascon and Dayer (1991), Olkkola etal. (1993, 1994) Backman et al. (1994, 1995, 1996), Wrighton and Ring (1994),
Ahonen et al. (1997).
metabolites are rapidly conjugated by glucuronic acid to form an inactive product
(Dundee et al. 1984). However, only very low levels of 4-hydroxymidazolam are
detected in plasma after taking midazolam (Mandema et al. 1992). The main
metabolite of midazolam, 1´-hydroxymidazolam, has also been shown to be
produced by CYP3A4 in vivo (Thummel et al. 1994a, b). Many diagnostic inhibitors
of CYP3A reduce the clearance of midazolam as discussed further below. Additional
indication of the involvement of CYP3A isoforms in the in vivo metabolism of
midazolam has been obtained from a study showing a signi® cant correlation between
midazolam clearance and the erythromycin breath test (Lown et al. 1995).
CYP3A4 is expressed in relatively large amounts in the luminal epithelium of the
small intestine (Kolars et al. 1994). Recently, it was shown that midazolam is
signi® cantly metabolised in the human small intestine (Paine et al. 1996). Therefore,
many clinically signi® cant drug interactions discussed below may occur in the small
intestine.
Inhibitors, activators and inducers of midazolam metabolism. The role of CYP3A
enzymes in midazolam metabolism has been further indicated by CYP3A speci® c
inhibitors. 1´-Hydroxymidazolam formation is inhibited by substrates and } or
inhibitors of CYP3A like cyclosporine, erythromycin, itraconazole, ketoconazole
and terfenadine (Gascon and Dayer 1991, Wrighton and Ring 1994, Goldberg et al.
1996). Further, midazolam has been shown to inhibit the metabolism of terfenadine
and quinine, which both are substrates of CYP3A (Jurima-Romet et al. 1994, Zhang
et al. 1997). As already discussed above, grapefruit juice inhibits the metabolism of
CYP3A4 substrates and it also inhibits midazolam metabolism (Kupferschmidt et
al. 1995, Ameer and Weintraub 1997). Large diå erences have been observed in the
ability of CYP3A inhibitors to inhibit midazolam metabolism in vitro and the results
are not always proportional to the in vivo situation. Relatively weak inhibitors of
midazolam metabolism, like erythromycin and verapamil, have been shown to be
potent inhibitors of midazolam metabolism in vivo (table 8). Further, azithromycin
which is as potent an inhibitor of midazolam metabolism as erythromycin in vitro,
did not inhibit midazolam metabolism in vivo at all (table 8). Therefore, it is not
always straightforward to make predictions of the in vivo situation based on in vitro
data. In the case of erythromycin, its inability to produce a signi® cant inhibitory
eå ect on CYP3A4 in vitro may be due to the fact that the mechanism of inhibition of
macrolide antibiotics occurs via metabolic-intermediate complexes with CYP3A
P450 inhibition and induction in man 1225
(Wrighton and Stevens 1992). Trolendomycin, another macrolide antibiotic,
produces a metabolic-intermediate complex rapidly (Murray 1987), whereas
erythromycin does it at a much slower rate (Wrighton and Ring 1994). Indeed, in the
in vivo situation where erythromycin was given for 5 days to the volunteers prior to
taking midazolam, a signi® cant interaction was observed between erythromycin and
midazolam (Olkkola et al. 1993). However, in a similar clinical study design
azithromycin was not able to inhibit midazolam metabolism (Backman et al. 1996).
Antimycotics, including ketoconazole, itraconazole and ¯ uconazole are potent
inhibitors of midazolam metabolism both in vitro and in vivo (table 8). Moreover,
their ability to inhibit midazolam metabolism is proportional to their in vitro
potency to inhibit 1´-hydroxymidazolam formation.
The stimulation of CYP3A isoforms has been shown also by using midazolam as
a substrate. Recently, a -naphtholavone was shown to be a potent stimulator of 1´-hydroxymidazolam formation (Ghosal et al. 1996, Ma$ enpa$ a$ et al. 1998). However,
a -naphtholavone had no eå ect on the CYP3A mediated 4-hydroxymidazolam
formation, although the inhibitors of midazolam metabolism have been shown to
inhibit both 1´-hydroxymidazolam and 4-hydroxymidazolam formation (Gascon
and Dayer 1991). Two other CYP3A substrates, terfenadine and testosterone,
regioselectively stimulated 1´-hydroxymidazolam formation and 4-hydroxy-
midazolam formation, respectively (Ma$ enpa$ a$ et al. 1998). The regioselective
stimulation of midazolam is another indication of the complexity of the regulation of
CYP3A enzymes. Further, the stimulatory potency of terfenadine was highly
dependent on the assay conditions used. Terfenadine was a potent inhibitor of
midazolam metabolism in certain assay conditions (buå er, ionic strength) whereas
it was a potent stimulator of midazolam metabolism in other assay conditions. Again
these factors further complicate the ability to make conclusions of drug interactions
in vivo based on in vitro data. 1´-Hydroxymidazolam formation was stimulated by a -
nephtho¯ avone in isolated human hepatocytes providing further evidence that the
stimulation of CYP3A may occur in vivo as well (Ma$ enpa$ a$ et al. 1998).
The eå ect of various CYP3A4 inducers like rifampicin, phenytoin and
carbamazepine have also been shown to dramatically decrease the Cmax
and AUC of
midazolam in man (Backman et al. 1996 (table 8). Further, the hypnotic eå ects of
midazolam were minimal in volunteers and patients after receiving inducing agents
(Backman et al. 1996). Therefore, when midazolam is given orally, inducers of
CYP3A4 should be avoided.
In vitro studies are a valuable tool to predict drug interactions in vivo in most
instances. However, caution should be exercised when extrapolating possible drug
interactions in vivo by using in vitro data, especially in the case of CYP3A substrates.
Exam ples of substrates and inhibitors with aæ nity for several CYPs
To illustrate induction and inhibition phenomena in connection with diå erent
chemicals, we present here in more detail some well-known drugs and groups of
drugs, which are extensively metabolized by several P450 enzymes. Admittedly,
warfarin is also oxidized by several CYPs, at least in vitro, but as described earlier,
by far the most important enzyme in vivo for warfarin metabolism is CYP2C9.
These examples have been selected so that possibilities of in vitro± in vivo
extrapolations are analysed in a more thorough fashion and that the clinical
relevance of induction and inhibition phenomena will be illuminated through some
examples.
1226 O. Pelkonen et al.
Table 9. Kinetics and CYP-associated catalysis of pathways of the oxidative metabolism of antipyrine.
Reaction Km
(m m ) "
Vmax
(nmol } mg*min) "
CYPs participating in thereaction #
4-hydroxylation 5.2± 23.1 0.57± 1.40 3A4(5) up to 65 %
1A2 about 30 %2A6, 2B6
N-demethylation 5.9± 26.3 0.34± 2.23 2C(9 } 19) 75± 80 %1A2 20± 25%
2A6, 2C8, 2C18, 2D6, 2E1, 3A3-Methylhydroxylation 9.0± 21.1 0.59± 1.41 1A2 50 %
2C(9) 50 %2C8, 2C9, 2E1
" Ranges for the Km
and Vmax
have been taken from Boobis et al. (1981), Engel et al. (1996) and Sharerand Wrighton (1996).
# Contributions of the major CYP(s) catalysing the reaction has been estimated on the basis ofdiagnostic inhibitors, antibodies, and recombinant expressed enzymes (Engel et al. 1996, Sharer and
Wrighton 1996).
Antipyrine
Antipyrine as a measure of in vivo oxidative drug metabolism has been very
extensively studied (almost 3000 references in a Medline search between 1961 and
1990, Poulsen and Loft, personal communication) and has been dealt with in a large
number of reviews (for references, see Poulsen and Loft 1988, Pelkonen and
Breimer 1994). The elimination rate of antipyrine is sensitive to induction by
antiepileptic and other drugs, by cigarette smoking and it is inhibited by various
liver diseases and several concomitantly administered drugs. The measurement of
urinary metabolites of antipyrine and thereby the rates of formation of metabolites
adds further information on the diå erential eå ects of inducing or inhibiting
substances with respect to diå erent isoforms, but this issue has only been
investigated to a limited extent (Poulsen and Loft 1988). Antipyrine seems to be a
quite useful and universal probe to detect the in¯ uence of common environmental
factors (including drug treatment) and disease processes on overall P450 activity.
Until very recently, there was not much information on isoforms involved in
antipyrine metabolism, except the classical inducers of the MC-type and the PB-
type aå ect the metabolic pathways diå erentially. However, on the basis of studies
with some diagnostic inhibitors it seemed probable that CYP2C (sulphaphenazole),
CYP2D (debrisoquine, quinidine) and CYP3A (nifedipine) or at least certain
enzymes belonging to these subfamilies do not participate in antipyrine metabolism
(Pelkonen and Breimer 1994).
The recent studies of Sharer and Wrighton (1996) and Engel et al. (1996) have
changed the situation completely. Through their work it is known that practically all
known hepatic P450 enzymes participate in the oxidative metabolism of antipyrine,
at least to a minor extent (table 9). Although the clearance of antipyrine via three
major metabolic pathways is roughly equal, all these individual pathways are
catalysed by several P450 enzymes with variable Km
and Vmax
characteristics. In this
light it becomes understandable why antipyrine has been characterized as ` a
general ’ probe and why almost any chemical exposure aå ects its clearance. On this
basis, antipyrine may be quite suitable for initial screening purposes, but does not
detect eå ects on speci® c CYP enzymes. Assessment of metabolite formation is only
of limited value in this respect.
P450 inhibition and induction in man 1227
However, three enzymes seem to be of major importance for antipyrine
clearance, namely CYP1A2, CYP2C(9) and CYP3A(4). Consequently, considering
the properties of these enzymes (see above) it becomes apparent why antipyrine
elimination is increased by cigarette smoking (CYP1A2 is induced) and antiepileptic
drugs (CYP3A4 and CYP2C9 are induced) and why a large number of drugs retard
its clearance (those three enzymes are responsible for the clearance of a majority of
pharmaceuticals, as far as is currently known). Typically, the eå ect of inducers or
inhibitors on antipyrine clearance is only about 10± 50 % (Poulsen and Loft 1988). It
is clear that these modest and clinically insigni® cant changes are due to multiple
CYP enzymes participating in antipyrine metabolism. Consequently, a general
probe such as antipyrine is not very eæ cient in revealing increases or decreases of
speci® c CYP enzymes. Furthermore, the impact of an environmental factor on the
elimination of a drug metabolized by a single CYP enzyme may be an order of
magnitude larger than what may erroneously be anticipated on the basis of
information obtained from antipyrine.
An early claim that the production of the main primary metabolites of antipyrine
is catalysed by polymorphically regulated P450 enzymes (Penno and Vesell 1983)
did not receive, even then, a complete acceptance. Whether correct or not, it was
thought that in most cases environmental and host factors in¯ uence the overall
antipyrine metabolism, which may therefore mask any polymorphic pattern in
metabolite formation. It is known that at least CYP2D6 participates in the
metabolism of antipyrine, but its contribution to the overall clearance is so small that
it is unlikely to have anything but an extremely minor eå ect. It is possible that there
is still an unrecognized polymorphism behind the ® ndings of Penno and Vesell
(1983), but this remains to be demonstrated.
Citalopram metabolism
Citalopram is a widely used antidepressant and is considered to be the most
selective of the serotonin selective reuptake inhibitors (SSRI). The terminal
elimination half-life of citalopram is 1.5 days. It is metabolized by successive N-
demethylations to N-desmethylcitalopram and N-didesmethylcitalopram, both of
which are detected in plasma, although the levels are roughly one-third and one-
tenth of the parent compound, respectively. Citalopram N-oxide and the deaminated
propionic acid derivative are minor urinary metabolites. About 10± 20 % of the drug
is excreted unchanged (Baumann and Larsen 1995).
Recent investigations on citalopram nicely illustrate the two major goals of in
vitro studies : (1) to identify CYP enzymes metabolizing a compound under study or
to which a compound has aæ nity without being metabolized, and (2) to analyse
whether it would have been possible to predict in vivo metabolism and potential
drug± drug interactions on the basis of in vitro data.
In vitro studies. The eå ect of citalopram on various CYP-speci® c model reactions
in human liver microsomes are presented in table 10. Aæ nities for most enzymes
studied are relatively low, with very little inhibition at concentrations ! 100 l m .
One exception is CYP2D6-catalysed reactions, for which Ki
vary from 5 to 19 l m
(Brosen 1994, 1996). Thus it seems that, CYP2D6 excluded, citalopram has a
relatively low aæ nity towards most human hepatic CYPs. Mainly due to the
1228 O. Pelkonen et al.
Table 10. Inhibitory eå ects of citalopram on CYP-speci® c model reactions in human liver microsomes.
CYP Reaction studied
% of control at
100 l m
citalopram Ki
( l m )
1A1 ethoxyresoru® n O-deethylation 82 " 100
1A2 ethoxyresoru® n O-deethylation 96 " 100
theophylline N-demethylations 92± 95 " 100
2A6 coumarin 7-hydroxylation 92 " 100
2C9 tolbutamide methylhydroxylation 88 " 100
2C19 S-mephenytoin 4-hydroxylation 78 " 100
2D6 dextromethorpan O-deethylation 7sparteine oxidation 5.1imipramine 2-hydroxylation 19
2E1 chlorzoxazone 6-hydroxylation 92 " 100
3A4 testosterone 6 b -hydroxylation 98 " 100cortisol 6 b -hydroxylation 71 " 100
Data derived from Rasmussen et al. (1995).
Table 11. Eå ects of diagnostic inhibitors on citalopram N-demethylation in human liver microsomes.
Inhibitor
Inhibitor
concentration( l m )
Inhibition(%) Prediction "
Fluvoxamine 12.5 " 10 1A2 1Furafylline 10 ! 5 1A2 –Phenacetin 10 ! 5 1A2 –
Coumarin 20 ! 5 2A6 –
Sulfaphenazole 10 ! 5 2C9 –
Omeprazole 100 " 10 2C19 1Mephenytoin 500 " 10 2C19 1
Quinidine 5 " 10 2D6 1Paroxetine 20 " 10 2D6 1
Methylpyrazole 20 ! 5 2E1 –DEDC 20 ! 5 2E1 –
Ketoconazole 2.5 " 10 3A4 } 5 1Troleandomycin 50 " 10 3A4 } 5 1
Data derived from Rochat et al. (1997) and Kobayashi et al. (1997)." 1 , Participation of the respective enzyme is predicted ; –, the contrary
to the plus sign.
relatively narrow range and low concentrations of citalopram used in those studies,
it is diæ cult to pinpoint low-aæ nity enzymes. In retrospect, it would have been
better to start with much higher (i.e. 1± 5 m m ) citalopram concentrations, which may
have allowed for the detection of low-aæ nity enzymes (see below).
Studies on citalopram N-demethylation in human liver microsomes in vitro have
revealed biphasic kinetics (Rochat et al. 1997). Consequently, there are at least two
major enzymes catalysing citalopram N-demethylation in vitro. High-aæ nity and
low-aæ nity components have roughly similar intrinsic clearances. Inhibition by
chemical inhibitors of citalopram N-demethylation has been studied by screening
experiments (table 11 ; Rochat et al. 1997). Studies with these ` diagnostic ’ inhibitors
P450 inhibition and induction in man 1229
Table 12. N-demethylation of citalopram enantiomers by cDNA-expressed human liver micrososal
cytochrome P450 enzymes.
CYP
Vmax
(pmol } h
3 pmol CYP) Km
( l m )
Intrinsicclearance
(CLi)
1A2 3.0 ND (high) ND
2A6 not detectable
2B6 not detectable
2C9 not detectable
2C19 S-CIT 78.1 198 0.39R-CIT 53.1 211 0.25
2D6 S-CIT 5.0 18.2 0.27
R-CIT 8.5 22.1 0.38
2E1 not detectable
3A4 S-CIT 62.1 169.0 0.37R-CIT 43.6 163.0 0.27
Data derived from Rochat et al. (1997) andKobayashi et al. (1997).
S-CIT and R-CIT refer to the S and R isomersof citalopram, respectively.
(table 2) suggest that at least CYP3A4 } 5, CYP2C19 and CYP2D6 participate in
citalopram N-demethylation. The role of CYP1A2 remains unclear, because the
inhibition results with ¯ uvoxamine could be explained on the basis of inhibition of
CYPs other than CYP1A2. Furthermore, furafylline and phenacetin, which are
probably more selective towards CYP1A2, do not inhibit citalopram N-demethyl-
ation at the concentrations used.
Citalopram N-demethylation by cDNA-expressed CYPs. Table 12 presents the
results obtained from two laboratories for the N-demethylation of citalopram by
cDNA-expressed human CYPs. Expressed enzymes with relatively high turnover
numbers were CYP2C19, CYP2D6, and CYP3A4. Also CYP1A2 showed little
activity. CYP2D6 seems to be a high-a æ nity enzyme, but intrinsic clearance
calculations demonstrated that all three enzymes were roughly equally active. When
compared with results obtained with human liver microsomes, CYP2D6 seems to
represent the high-aæ nity (but low capacity) component, and CYP2C19 and
CYP3A4 the low-aæ nity component.
Although there is substantial interindividual variability in the content of the
individual CYP enzymes, it can be assumed on the basis of studies using human liver
microsomes in vitro that CYP3A, CYP2C19 and CYP2D6 represent about 30, 4 and
2 % of total P450 content, respectively (Shimada et al. 1994). Because the intrinsic
clearances of drugs by these CYPs are rather similar (see above), their contributions
to the overall metabolism of citalopram should be in the order of their abundance.
Studies on the diagnostic inhibitors point to the same conclusion : ketoconazole
inhibited approximately 60 % of the microsomal N-demethylation of citalopram,
whereas the percentages for omeprazole (CYP2C19) and quinidine (CYP2D6) were
maximally 30 and 15 of total N-demethylation, at their CYP-speci® c concentrations.
In conclusion, the major P450 enzymes catalysing the principal pathway of
citalopram metabolism, N-demethylation, have been shown to be CYP3A4,
CYP2C19 and CYP2D6. The aæ nity of CYP2D6 is roughly one order of magnitude
1230 O. Pelkonen et al.
Table 13. Inhibition of CYP2D6-mediated desipramine 2-hydroxylation by SSRI-compounds in
human liver microsomes in vitro and calculated inhibition in vivo.
SSRI
Ki
( l m ) "
Cmax
( l m ) #
Inhibitionin vivo
(%) $ Eå ect in vivo %
Fluoxetine 3, 0.6 1 (94) 25 " 350 %Nor¯ uoxetine 2, 0.43 1 (94) 33 " 350 %
Fluvoxamine 20, 8.2 1 (77) 5 14 %Paroxetine 2, 0.15 0.2 (95) 10 " 300 %
Sertraline 20, 0.7 0.1 (99) 0.5 26± 72 %Norsertraline 15, NK 0.1 0.7 26± 72 %
Citalopram 80, 5.1 0.4 (70) 0.5 46 %Norcitalopram " 100, NK 0.4 ! 0.5 46 %
Quinidine 0.05 10 100 potent
" First Ki
values are taken from Moltke et al. (1994) and are based on
inhibition of desipramine 2-hydroxylation activity, except for citalopram andnorcitalopram, for which the values are calculated on the basis of relative
inhibition of imipramine 2-hydroxylation (Skjelbo and Brosen 1992). Thesecond values are for sparteine oxidation in vitro (Brosen 1993). NK, not
known.# C
maxdenotes the (peak) plasma concentration of a SSRI drug in vivo
( l m ). Plasma protein binding (in parentheses), which aå ect the free con-centration, has not been taken into consideration. Liver } plasma partition ratio
has been assumed to be 1, although it may actually be considerably higher forsome SSRIs. It should be stressed that ¯ uoxetine and nor¯ uoxetine both
together produce plasma concentration of about 1 l m .$ Assuming competitive inhibition and the substrate concentration ’ K
mfor desipramine metabolism, the percentage inhibition was calculated ac-cording to the equation I } (I 1 K
i) 3 100.
% Percent increase in the area under the plasma concentration-time curve ofdesipramine (AUC) (Brosen 1996). In vivo data on sparteine elimination
(Jeppesen et al. 1996) is in a good agreement with desipramine data.
greater than that of CYP3A4 or CYP2C19, but the intrinsic clearances of these
enzymes are roughly equal. Consequently, because of the relative abundances of
these enzymes, none of them is overwhelmingly important for the clearance of
citalopram and one would not expect any major consequences for induction or
inhibition of P450 enzymes. This speci® c point is further elaborated in the next
section.
SSRI-antidepressants and quantitative prediction of drug± drug interactions
There are some quantitative in vitro inhibition and aæ nity data available for
all ® ve SSRI-compounds for CYP2D6 and CYP3A4 interactions which make it
possible to calculate potential in vivo inhibition for representative CYP2D6-,
CYP3A4-, and CYP1A2-catalysed metabolic reactions (desipramine, midazolam
and phenacetin, respectively).
With respect to CYP2D6 (on the basis of the data in table 13) clinically relevant
concentrations of nor¯ uoxetine and ¯ uoxetine seem to lead to a signi® cant in vivo
inhibition of the CYP2D6-mediated 2-hydroxylation of desipramine. Also
paroxetine and ¯ uvoxamine are calculated to cause some inhibition. Comparison of
the inhibitory potencies of ¯ uoxetine (plus nor¯ uoxetine) and paroxetine observed
in in vivo studies are in line with in vitro inhibition results when sparteine oxidation
was used as a model reaction for CYP2D6, whereas the potency of paroxetine would
P450 inhibition and induction in man 1231
Table 14. Aæ nity of SSRI-compounds for CYP3A4 in human liver microsomes in vitro, and calculated
inhibition of in vivo midazolam metabolism (according to von Moltke et al. 1994, 1996).
SSRIAæ nity invitro ( l m ) " C
max( l m ) # I in vivo (%) $ Eå ect in vivo %
Fluoxetine 7.1, 44.3 1 (94) 12.3, 2.2 detectable ?
Nor¯ uoxetine 2.7, 8.0 1 (94) 27.0, 11.1 detectable ?Fluvoxamine 5.6, 20.2 1 (77) 15.2, 4.7 detectable ?
Paroxetine 3.8, 14.3 0.2 (95) 5.0, 1.3 absentSertraline 3.5, 20.3 0.1 (99) 2.8, 0.5 absent
Norsertraline 3.5, 10.7 0.1 2.8, 0.9Citalopram 165 0.4 (70) 0.2 absent
Ketoconazole 0.02 10 100 strong
" Aæ nity values are Kiof inhibition of two midazolam CYP3A4-mediated reactions (von Moltke et
al. 1996), except for citalopram where the value is the Km
for citalopram N-demethylation (Rochat et al.1997).
# Cmax
denotes the (peak) plasma concentration of a SSRI drug in vivo ( l m ). Plasma protein binding(in parentheses), which aå ect the free concentration, has not been taken into consideration. Liver } plasma
partition ratio has been assumed to be 1, although it may actually be considerably higher for some SSRIs.It should be stressed that ¯ uoxetine and nor¯ uoxetine both together produce plasma concentration of
about 1 l m .$ Assuming competitive inhibition and the substrate concentration ’ K
mfor midazolam metabolism,
the percentage inhibition was calculated according to the equation I } (I 1 Ki) 3 100.
% Assessment is based on Nemeroå et al. (1996). Eå ect in vivo means whether interaction with other
CYP3A4-catalysed reactions have been observed in vivo.
have been underestimated if the 2-hydroxylation of desipramine had been used as a
model reaction. It seems that various model reactions may lead to both under-
estimation or overestimation of the inhibitory potency of a particular SSRI.
However, for example, plasma protein binding and liver to plasma concentration
ratios have not been taken into consideration and may be of importance in such
calculations (von Moltke et al. 1994).
With respect to CYP3A4 (table 14), calculations indicate that nor¯ uoxetine
(which is the predominant plasma constituent of long-term ¯ uoxetine treatment)
and ¯ uvoxamine potentially cause in vivo inhibition " 15 % of midazolam
metabolism. There is some evidence that ¯ uoxetine treatment actually leads to
increased plasma concentrations and } or retarded elimination of alprazolam, carba-
mazepine, terfenadine and diazepam whereas ¯ uvoxamine treatment inhibits the
elimination of alprazolam and terfenadine (Nemeroå et al. 1996). However, the data
of Stevens and Wrighton (1993) do not support a signi® cant inhibition of midazolam
hydroxylation by ¯ uoxetine. With respect to citalopram, the only values for aæ nities
for CYP3A4 are available from Rochat et al. (1997) and Rasmussen et al. (1995) and
are 165 and " 100 l m , respectively, indicating a relatively low aæ nity and making
it unlikely that citalopram would cause drug± drug interactions via CYP3A4.
With respect to CYP1A2, only ¯ uvoxamine seems to have a high enough aæ nity
for the enzyme to cause clinically signi® cant interactions (table 15). Actually these
comparative studies previously led to suggestions that ¯ uvoxamine might be the
inhibitor of choice for CYP1A2. However, recent results suggest that ¯ uvoxamine
has a relatively high aæ nity towards some other CYP enzymes (Rochat et al. 1997).
1232 O. Pelkonen et al.
Table 15. Ability of SSRI-antidepressants and their metabolites to inhibit CYP1A2-mediated reactions
vitro and in vivo.
Drug Ki
( l m ) " Cmax
( l m ) # I in vivo (%) $ Eå ect in vivo %
Fluoxetine " 100 1 (94) ! 1 caå eine ( –)clozapine ( 1 ?)
Nor¯ uoxetine " 100 1 (94) ! 1 ?
Fluvoxamine 0.2 1 (77) 83 caå eine ( 1 1 1 )
theophylline ( 1 1 1 )clozapine ( 1 1 1 )
imipramineamitriptyline
clomipramine
Paroxetine 45 0.2 (95) 0.4 caå eine ( –)
Sertraline 70 0.1 (99) 0.1 not known
Citalopram " 100 0.4 (70) ! 0.4 caå eine ( –)
" Ki
in vitro for phenacetin O-deetylation (Brosen et al. 1993).# C
maxdenotes the (peak) plasma concentration of the SSRI drug in vivo ( l m ). Plasma protein binding
(in parentheses), which aå ect the free concentration, has not been taken into consideration. Liver } plasma
partition ratio has been assumed to be 1, although it may actually be considerably higher for some SSRIs.It should be stressed that ¯ uoxetine and nor¯ uoxetine both together produce plasma concentration of
about 1 l m .$ Assuming competitive inhibition and the substrate concentration ’ K
mfor desipramine metab-
olism, the percentage inhibition was calculated according to the equation I } (I 1 Ki) 3 100.
% Caå eine results from Jeppesen et al. (1996) : ( 1 1 1 ) strong, ( 1 1 ) moderate and ( 1 ) slight eå ect
on caå eine elimination in vivo, ( –) very small or absent eå ect.
Induction
Induction in general
Classically, the de® nition of induction is the de novo synthesis of new enzyme
molecules as a result of an increased transcription of the respective gene after an
appropriate stimulus. However, in drug metabolism research the term induction has
been used as a generic term, describing an increase in the amount and } or activity of
a drug metabolising enzyme as a result of an exposure to an ` inducing chemical ’ ,
whatever the underlying mechanism. However, in the usual sense of induction,
there is a certain lag phase before an increase in enzyme activity can be observed.
This lag phase is due to the fact that, whatever the underlying mechanism, it takes
time to increase the amount of enzyme molecules, either as a result of increased
transcription and translation or as result of the stabilisation of an enzyme by a
substrate, which leads to a new steady-state level between synthesis and degradation.
An increase in enzyme activity, due to activation, is not usually included under
the term induction. Some examples include the eå ect of dexamethasone on the
elimination of some drugs and a rapid enhancement of antipyrine elimination by
heme arginate in porphyric patients (Mustajoki et al. 1992), probably is due to the
restoration of holoenzyme by heme in the presence of intact apoenzyme.
Based on mostly animal experiments, inducers have been categorised into several
classes (table 16), which can be characterized mainly on the basis of the spectrum of
enzymes induced and the potency of induction. This table gives only a qualitative
view of the spectrum and mechanisms of induction and in the following section more
background is given on mechanistic details and quantitative aspects of induction in
man or human-derived systems. It has to be stressed that in many cases we have to
rely on what we know from animal experiments.
P450 inhibition and induction in man 1233
Table 16. Classi® cation of inducers of drug-metabolizing enzymes.
Class Prototype inducer Principal enzymes aå ected
PAH-type 2,3,7,8-
Tetrachlorodibenzo-p-dioxin
CYP1A, UDP-
glucuronosyltransferase
Ethanol-type Ethanol CYP2E1
Phenobarbital-type Phenobarbital CYP1A, CYP2A, CYP2B, CYP3A
Glucocorticoid-type Dexamethasone CYP3A
Peroxisome proliferator-type Clo® brate CYP4
This classi® cation is based mainly on animal studies, and the types of induction are not as clear-cutin man.
Quantitation of induction
The basic tenet is that induction leads to an increased amount of an existing
enzyme (or enzymes) and not to a qualitatively diå erent enzyme. This means that
in the quantitative analysis the only changing measure is Vmax
. Obviously, when
more than one enzyme is induced, calculations will become more complicated, but
still there are no ` new ’ players present. The overall eå ect in vivo will still depend on
the aæ nities and rates of metabolism of various enzymes participating in the
metabolism of a compound under study.
Spectrum and mechanisms of induction
Several individual agents that induce CYP enzymes have been identi® ed in man,
and the list of drugs whose pharmacokinetics and pharmacodynamics are aå ected by
induction is rather long. For comprehensive updates on such drugs the reader is
referred to relevant monographs (Wrighton and Stevens 1992, Goldstein and de
Morais 1994, Guengerich 1995, Wilkinson 1996). Only the basic classes of induction
as well as the mechanisms involved will be dealt with here.
Cigarette smoking and PAH-like inducers. Decreased half-life and } or increased
clearance of several drugs have been demonstrated in smokers (Sotaniemi and
Pelkonen 1987). The common denominator for these drugs is that they are
metabolised by CYP1A forms. Examples include theophylline, caå eine, antipyrine,
imipramine, paracetamol (acetaminophen), and phenacetin (table 5). The metab-
olism of these drugs is mediated predominantly by CYP1A2, which represents
approximately 10 % of the total hepatic P450 content (Shimada et al. 1994). Not
only CYP1A-mediated reactions, but also glucuronide conjugation of, for example,
mexiletine is increased due to cigarette smoking (Sotaniemi and Pelkonen 1987).
The inducing eå ects of cigarette smoking are attributed to the polycyclic aromatic
hydrocarbon (PAH) class of compounds. Consistent with this, CYP1A2 activity is
increased in human primary hepatocytes by the prototype PAH inducer 3-
methylcholanthrene (Morel et al. 1990).
CYP1A1 is mainly an extrahepatic enzyme. It is highly induced in the lung,
mammary gland, lymphocytes, and placenta by PAHs and cigarette smoke (Raunio
et al. 1995). The regulatory mechanisms of CYP1A induction have been thoroughly
elucidated (Hankinson 1995). CYP1A inducers interact with the so-called Ah (Aryl
1234 O. Pelkonen et al.
hydrocarbon) receptor, which upon ligand binding is activated and translocated to
the nucleus as a complex which includes also the ARNT (aryl hydrocarbon nuclear
translocator) protein. The complex binds to speci® c regions in the regulatory areas
of the CYP1A genes, the Ah-receptor regulatory elements (AhRE), also known as
xenobiotic- or drug-responsive elements. This interaction leads to increased
transcription of the CYP1A genes and the de novo production of CYP1A protein.
Increased amounts of CYP1A enzymes may have two diå erent types of conse-
quences : increased toxicity due to more eæ cient activation of protoxins and
procarcinogens that are substrates of these enzymes (toxic response), or decreased
toxicity as a result of enhanced inactivation reactions (adaptive response) (Schmidt
and Brad® eld 1996).
The CYP1A1 gene is distributed in a polymorphic pattern in the human
population. The two main variant alleles CYP1A1 are an MspI RFLP in the 3´-noncoding region of the gene, and a second one is the closely linked point mutation
in exon 7, creating a substitution of valine % ’ # for isoleucine % ’ # (Kawajiri et al. 1993).
Several attempts have been made to correlate these polymorphisms to the
inducibility and function of the CYP1A1 enzyme. The initial reports (Petersen et al.
1991, Landi et al. 1994) on the higher inducibility of the MspI allele compared with
the wild-type allele have been questioned in other studies in which no diå erences in
the induction properties between these two alleles were found (Crofts et al. 1994,
Wedlund et al. 1994, Jacquet et al. 1996). Recent studies with heterologously
expressed CYP1A1Val % ’ # alleles clearly show that the catalytic and kinetic properties
of this enzyme do not diå er from those of the wild-type (CYP1A1Ile % ’ # ) enzyme
(Zhang et al. 1996, Persson et al. 1997). It may be that the high-inducibility
CYP1A1 phenotype will be explained by variations in the regulatory genes rather
than the structural gene. Despite convincing evidence that mutations in the Ah-
receptor gene confer high and low inducibility in inbred strains of mouse, attempts
to correlate CYP1A1 inducibility with known polymorphisms in the human AH-
receptor gene have yielded negative results (Micka et al. 1997).
The regulation of CYP1A2 is not as well characterized as that of CYP1A1. It is
inducible by smoking, charbroiled food, cruciferous vegetables, omeprazole and
even vigorous exercise (Wrighton and Stevens 1992a, Guengerich 1995a). Induction
of CYP1A2 by PAHs is mainly transcriptional and involves the Ah-receptor, but
also other, currently unknown factors (Quattrochi et al. 1994). Two CYP1A2 knock
out mouse strains have been constructed (Pineau et al. 1995, Liang et al. 1996).
These mice develop normally apart from de® cient metabolism of some xenobiotics
metabolised by CYP1A2. Thus CYP1A2 appears not to have any crucial endogenous
function.
CYP1B1, a novel member in the CYP1 family, has catalytic properties similar
but not identical to CYP1A members (Shimada et al. 1996). In rodents, CYP1B1
is highly inducible by PAHs in several extrahepatic tissues, but the inducibility in
human tissues appears to diå er from that of CYP1A1 (Hakkola et al. 1997).
Omeprazole and congeners. The CYP1A-inducing capacity of omeprazole in the
human liver and primary hepatocytes was ® rst reported in 1990 by Diaz et al. (1990).
Shortly afterwards, omeprazole was shown to induce CYP1A also in the human
alimentary tract (McDonnell et al. 1992). Both of these ® ndings have been con® rmed
by diå erent methodological approaches (Nousbaum et al. 1994, Buchthal et al. 1995,
Kash® et al. 1995), but also negative ® ndings have been reported, especially using
P450 inhibition and induction in man 1235
the standard therapeutic doses of omeprazole (Andersson et al. 1991, Galbraith and
Michnovicz 1993, Rizzo et al. 1996). In human primary hepatocytes, omeprazole
and lanzoprazole also appear modestly to induce CYP3A members (Curi-Pedrosa et
al. 1994), and both agents stimulate CYP1A1 in the human colon adenocarcinoma
derived cell line Caco-2 (Daujat et al. 1996).
Omeprazole is not a direct ligand for the Ah receptor (Daujat et al. 1992, Curi-
Pedrosa et al. 1994, Lesca et al. 1995). However, the induction of CYP1A by
omeprazole is mediated by enhanced translocation of the Ah receptor to the nuclei
and binding to the regulatory elements upstream of the CYP1A coding genes
(Quattrochi and Tukey 1993). Recent evidence suggests that omeprazole is
metabolised to a sulfenamide intermediate that interacts with the ligand binding
domain of the Ah-receptor (Dzeletovic et al. 1997). The inducing eå ect is strictly
species speci® c, since the CYP1A1 gene is activated in man but not in mouse
hepatocytes, possibly due to a repressor mechanism in mouse cells (Kikuchi et al.
1995, Dzeletovic et al. 1997). Thus, omeprazole is an addition to the growing list of
agents that induce CYP1A by activating the Ah-receptor without binding directly to
it, possibly involving ligand binding of a metabolite or inducer-elicited changes in
the phosphorylation of proteins regulating the Ah-receptor (Hankinson 1995).
The overall omeprazole-dependent increases in CYP1A activities in the liver and
gut in vivo and rather low (usually ! 2-fold) and high doses and } or prolonged
treatments are needed to produce the inducing eå ect. In addition, the inducibility of
CYP1A2 by omeprazole is aå ected by the CYP2C19 status, since omeprazole is
metabolized by CYP2C19. For example, a dose of 120 mg } day omeprazole for
7 days causes ! 30 % increase in the N-3-demethylation of caå eine in vivo in
CYP2C19 extensive metabolizers, whereas a 40 % increase is elicited in CYP2C19
poor metabolizers (Rost and Roots 1994). The inducing eå ect using the standard
dose of 40 mg } day is pronounced only in individuals having a defective CYP2C19
enzyme (Rost et al. 1992, 1994, Sarich et al. 1997). Taken together, the evidence
suggests that the induction caused by omeprazole is unlikely to have practical
consequences. Concerns that elevated CYP1A levels due to omeprazole could result
in increased procarcinogen activation or acetaminophen toxicity do not appear to be
substantiated, since the magnitude of induction is so small compared with cigarette
smoking, and no such adverse eå ects have been associated with omeprazole
treatment (Petersen 1995). The clinical use of omeprazole and related proton pump
inhibitors is currently extensive all over the world and major drug interactions due
to induction have not been reported. In line with this notion, a recent study (Sarich
et al. 1997) reported that the omeprazole-elicited 75 % increase in plasma clearance
of caå eine, as a marker of induced CYP1A2 activity, is not accompanied by changes
in the metabolic activation of paracetamol.
Ethanol. Ethanol induces liver drug metabolism in man as measured by both in
vivo and in vitro parameters (Sotaniemi and Pelkonen 1987). The presence of an
inducible microsomal ethanol-oxidizing enzyme system, clearly distinct from
alcohol dehydrogenases and catalases, was reported in the late 1960s (Lieber and
DeCarli 1968). This system has been characterized in great detail, and it has become
evident that CYP2E1 is the mediator of the inducible oxidation of ethanol and it may
metabolize up to 10 % of the ingested alcohol (Fraser 1997). CYP2E1 also
metabolizes a wide variety of drugs and toxic chemicals, including several
procarcinogens, making its inducibility of great practical importance (Lieber 1997).
1236 O. Pelkonen et al.
Tsutsumi et al. (1989) reported that the amount of immunodetectable CYP2E1
apoprotein in the liver was 4-fold higher in alcoholics than in non-drinkers or
alcoholics who had abstained from drinking. Ethanol intake causes up to a 3-fold
elevation in the amounts of both CYP2E1 protein and mRNA in the human liver
(Perrot et al. 1989, Takahashi et al. 1993). The plasma clearance of chlorzoxazone,
a drug metabolized by CYP2E1, is increased almost 2-fold in individuals consuming
excessive amounts ( " 300 g } day) of alcohol (Girre et al. 1994).
Of the numerous other agents capable of CYP2E1 induction in the rat (Ronis et
al. 1996), isoniazid also appears to be an inducer in man since it increases the in vivo
metabolism of en¯ urane (Mazze et al. 1982) and chlorzoxazone (Zand et al. 1993).
Isoniazid is also an inhibitor of the CYP2E1 enzyme and therefore a washout period
of 48 h after the last dose of a prolonged regimen of isoniazid administration is
needed for a manifest inducing eå ect to occur (O ’ Shea et al. 1997). The inducing
eå ect is dependent on the N-acetylation status, either slow or extensive acetylators
being more prone to CYP2E1 induction depending on the length of the washout
period applied (Chien et al. 1997, O ’ Shea et al. 1997).
Like most other CYP forms, CYP2E1 is expressed at highest levels in the
perivenous hepatocytes (zone 3) with a diminishing gradient towards the periportal
area (zone 1) (Lindros 1997). In rat and man, ethanol-dependent increases in
CYP2E1 expression occur in both the perivenous and midzonal areas (Takahashi et
al. 1993). In primary human hepatocytes, ethanol treatment increases the activity of
p-nitrophenol hydroxylase (Donato et al. 1995) and elevates the amounts of CYP2E1
and CYP3A apoproteins (Kostrubsky et al. 1995). In HepG2 cells transfected with
the coding sequence of CYP2E1 cDNA, ethanol increased CYP2E1 protein but not
mRNA levels, indicating that the elevation is due to protein stabilization (Carroccio
et al. 1994).
The mechanism of CYP2E1 induction by ethanol has been extensively studied in
the rat, and due to the conserved nature of the CYP2E1 gene and protein, the
regulation of induction may be similar in man. During chronic ethanol intake,
CYP2E1 induction occurs in two phases : at blood levels ! 300 mg } dl the CYP2E1
protein levels are increased without changes in mRNA, and higher blood ethanol
levels also cause increases in the amount CYP2E1 mRNA (Ronis et al. 1996). The
mechanisms of increases in CYP2E1 protein levels include enhanced translation and
protein stabilization. One mechanism for stabilization of CYP2E1 is protection of
the protein from cAMP-mediated degradation by the enzyme-bound substrate
(Eliasson et al. 1992). Likewise, CYP2E1 mRNA levels are elevated by increased
transcription or stabilization of the message, depending on the stimulus causing
induction (Ronis et al. 1996). DNA footprinting analysis of the ® rst kilobase of the
CYP2E1 5´-¯ anking sequence revealed 13 protected regions, but none appeared to
participate in enhanced transcription of the CYP2E1 gene, indicating that regions
further upstream of the gene may be involved in ethanol-mediated increase of
transcription (McGehee et al. 1997).
Several polymorphisms in the CYP2E1 gene have been detected. Of these
polymorphisms, the one generating a PstI site and the lack of a RsaI site in the 5´-¯ anking region of the CYP2E1 gene (so-called c2 allele) has been reported to confer
higher transcriptional activity and elevated enzymatic activity than the wild-type
allele among Japanese population (Watanabe et al. 1994). In an in vivo study using
chlorzoxazone metabolism as a marker, Lucas et al. (1995) did not detect any
diå erences in basal CYP2E1 activities in Caucasian individuals carrying the c2 allele
P450 inhibition and induction in man 1237
versus wild-type homozygotes, and the inducing eå ect of ethanol appeared to be
weaker in individuals with the mutated CYP2E1 alleles. Thus, it is likely that
additional factors, perhaps other mutations in the CYP2E1 gene (Hu et al. 1997) will
explain the discordant results concerning high CYP2E1 inducibility.
Phenobarbital and other antiepileptic drugs. Phenobarbital is the archetypical
inducer of drug metabolism (Waxman and Azaroå 1992). Phenobarbital is still
being used in the therapy of epilepsy, and it has long been known to be a strong and
broad-spectrum in vivo inducer of drug metabolism. As an example of the potency
of induction, the dose of warfarin required for the anticoagulant eå ect can be
increased up to ten-fold during phenobarbital treatment (Patsalos and Duncan
1993). Also other antiepileptic drugs, especially phenytoin and carbamazepine, have
been shown to induce drug metabolism in man (Perucca 1978, Park and
Breckenridge 1981, Brodie 1992). For example, phenytoin therapy strongly reduces
the Cmax
and AUC of cyclosporin A in vivo (Freeman et al. 1984), and studies in
human primary hepatocytes have shown that phenytoin elevates the activity of
cyclosporin A oxidase (Pichard et al. 1990). Carbamazepine is a broad-spectrum
inducer, enhancing the metabolism of numerous drugs, including warfarin,
theophylline, oral contraceptives and carbamazepine itself (autoinduction) (Brodie
and Dichter 1996).
In rodents, phenobarbital induces CYP forms in several subfamilies, including
CYP1A, CYP2A, CYP2B and CYP3A, the members in the CYP2B subfamily
reacting most sensitively (Waxman and Azaroå 1992). Several lines of evidence
suggest that in man the CYP3A forms are the ones most aå ected by phenobarbital,
carbamazepine and other antiepileptic drugs (Roots et al. 1979, Ohnhaus et al. 1989,
Bertilsson et al. 1997). Recent data obtained with primary human hepatocytes
suggest that CYP2B6 is also inducible by phenobarbital as well as by rifampicin and
dexamethasone (Chang et al. 1997). In addition, members of the CYP2C subfamily
(CYP2C8 and CYP2C9) are inducible by these agents (Morel et al. 1990, Chang et
al. 1997), and there is also evidence for the in vivo induction of CYP2A6 in response
to antiepileptic drug treatment (Rautio et al. 1994). The inducing eå ect of
antiepileptic drugs on several CYP forms explains the clinical observations that
several of the antiepileptics aå ect a number of structurally unrelated pharma-
ceuticals by reducing their bioavailability.
The new antiepileptic drugs gabapentin (Goa and Sorkin 1993), lamotrigine
(Goa et al. 1993), and vigabatrin (Connelly 1993) appear to be devoid of clinically
signi® cant inducing properties. Oxcarbazepine, the 10-keto-derivative of carba-
mazepine, lacks autoinduction properties and does not a å ect the pharmacokinetics
of warfarin (Ka$ lvia$ inen et al. 1993). In a prospective study, Isoja$ rvi et al. (1994)
showed that replacing carbamazepine with oxcarbazepine resulted in an increase in
the half-life and a decrease in the clearance of antipyrine, re¯ ecting a normalization
of liver CYP function. Although clearly being a less potent CYP inducer than
carbamazepine, oxcarbazepine reduces the bioavailability of ethinylestradiol and
levonorgestrel, thus diminishing the action of oral contraceptives containing these
hormones (Jensen et al. 1992, Ka$ lvia$ inen et al. 1993).
The mechanisms mediating phenobarbital induction in rodents have not yet
been thoroughly characterised. It appears that there are no cellular receptors
binding phenobarbital. Rather, the induction is a consequence of complex
rearrangements in putative positive and negative regulatory proteins acting at the 5´-
1238 O. Pelkonen et al.
regulatory region of the responsive CYP genes (Waxman and Azaroå 1992). Despite
a greatly increased knowledge on the regulatory factors mediating phenobarbital
induction in experimental animals, virtually nothing is known abut the mechanisms
of induction of the human CYP forms by phenobarbital and other antiepileptic
drugs.
Rifampicin and corticosteroids. Rifampicin is a widely used antibiotic for the
treatment of tuberculosis. The inducing eå ects of rifampicin on drug metabolism in
vivo were noticed soon after its introduction to clinical practice (Baciewicz and Self
1984, Baciewicz et al. 1987). For example, rifampicin accelerates the elimination of
quinidine, 17a-ethinylestradiol, cyclosporine and a number of other drugs
(Venkatesan 1992). Consistent with the fact that most drugs aå ected by rifampicin
are substrates of CYP3A4, rifampicin has been shown to induce mainly CYP3A
enzymes in the liver in vivo (Watkins et al. 1985, Ged et al. 1989). Slight inducing
eå ects on metabolic pathways mediated by other CYP forms have also been reported
(Kostrubsky et al. 1995).
Human primary hepatocytes have proved to be very sensitive to the inducing
eå ect of rifampicin. Treatment of primary hepatocytes with rifampicin produces
increases in several CYP3A-mediated catalytic activities, including oxidation of
cyclosporine (Pichard et al. 1990), lidocaine (Li et al. 1995), and the oxaza-
phosphorine cancer drugs cyclophosphamide and ifosfamide (Chang et al. 1997).
These eå ects are caused by rifampicin concentrations that are equal to the 2± 30 m m
serum concentrations achieved after standard therapeutic doses (Acocella 1978).
Rifampicin increases the amounts of CYP3A4 mRNA and apoprotein, but does not
aå ect the amount of CYP3A5 in primary hepatocytes (Schuetz et al. 1993, Chang et
al. 1997). A more pronounced eå ect on CYP3A4 was noticed in HepG2 cells, and
CYP3A7 was also elevated in this cell line (Schuetz et al. 1993). An interesting
® nding is that the mRNA encoding CYP3A7, a form present almost exclusively in
the foetal liver, is inducible by rifampicin in primary hepatocytes derived from adult
liver (Greuet et al. 1996). CYP3A5 appears to be induced by rifampicin in human
colon carcinoma-derived cell lines (Schuetz et al. 1996). In addition to its inducing
eå ects on CYP3A, rifampicin elevates also CYP2A (Dalet-Beluche et al. 1992) and
CYP2C (Morel et al. 1990) apoprotein levels in human primary hepatocytes,
resembling phenobarbital in this respect.
CYP3A enzymes are also present at high levels in the human alimentary tract
(Kaminsky and Fasco 1992). Induction of CYP3A4 has been shown to occur in small
bowel enterocytes in response to rifampicin treatment (Kolars et al. 1992). Using the
CYP3A4 substrate cyclosporine as a marker, Hebert et al. (1992) reported that
rifampicin treatment decreases cyclosporine bioavailability more than would be
predicted from by increased hepatic metabolism. This phenomenon was ascribed to
an elevation of intestinal CYP3A4-mediated metabolism of cyclosporine (Hebert et
al. 1992). This is important, since combination of cyclosporine with CYP inducers
leads to decreased cyclosporine concentrations in blood and the risk of organ
rejection, and, upon termination of CYP-inducing drug therapy, cyclosporine
concentrations rise to levels which may cause adverse eå ects (Christians and Sewing
1993).
The induction of drug metabolism has been claimed to be also the primary cause
of drug interactions observed with corticosteroids. The analysis of inducing
properties of corticosteroids is complicated by the fact that they are often also
P450 inhibition and induction in man 1239
Figure 2. Role of metabolism in the detoxi® cation and activation of paracetamol. Paracetamol is
normally eliminated as glucuronide and sulphate conjugates. If ingested in high doses ( "4 g } day), these pathways can be saturated, and more of the parent compound is available for CYP
enzymes to convert to the reactive intermediate NAPQI. This metabolite is scavenged byglutathione S-transferase, but if the hepatocyte glutathione stores are depleted, formation of
macromolecule adducts with NAPQI occurs in the liver. Conditions which enhance thetoxi® cation process (CYP induction) or decrease the detoxi® cation functions (malnourishment,
diseases) augment paracetamol toxicity. Adapted from Zimmerman and Maddrey (1995), Parket al. (1996). SG, glutathione adduct.
substrates and hence inhibitors of the reactions under study. For example,
methylprednisolone, prednisolone, and prednisone either increase or decrease
cyclosporin A clearance, depending on the experimental set-up (Christians and
Sewing 1993). However, CYP3A4 expression is increased due to dexamethasone
treatment in vivo (Molowa et al. 1986), and dexamethasone increases the catalytic
activities mediated by CYP3A4 in human primary hepatocytes (Pichard et al. 1990,
Donato et al. 1995). Prednisone, but not prednisolone or methylprednisolone,
elevates the amounts of CYP3A mRNA, protein, and catalytic activity in human
primary hepatocytes (Pichard et al. 1992).
CYP3A4 is inducible not only by rifampicin and glucocorticoids but also by
phenobarbital, phenytoin, clotrimazole, spironolactone, and sulfadimidine (Watkins
et al. 1985, Pichard et al. 1990, Morel et al. 1990, Kocarek et al. 1995). The 5´
1240 O. Pelkonen et al.
regulatory region of the CYP3A4 gene contains putative binding sites for the
glucocorticoid receptor and an element designated NFSE (P450NF-speci® c
element), which may participate in the induction process (Hashimoto et al. 1993).
Functional analysis proving this is still lacking. Recently, the induction of CYP3A5
by glucocorticoids was shown to be mediated by a 219-bp enhancer, which
contained two glucocorticoid-responsive element half-sites (Schuetz et al. 1996).
This sequence is unique to CYP3A5, since a similar sequence is lacking from
CYP3A4 and the rat CYP3A1 (Schuetz et al. 1996). In addition, other consensus
sequences possibly mediating induction in the promoter regions of CYP3A genes
have been described, and it has become apparent that the host cell environment also
strongly in¯ uences the inducibility of CYP3A genes (Barwick et al. 1996).
In individuals who are extensive metabolisers of debrisoquine (normal CYP2D6
function), 3-week rifampicin pretreatment caused a reduction in morphine plasma
concentrations and a signi® cant attenuation of codeine’ s respiratory and psycho-
motor eå ects after a single dose of codeine (Caraco et al. 1997). This may be
explained by an induction of hepatic CYP3A4, which is the major enzyme mediating
codeine N-demethylation, an inactivating pathway competing with the morphine-
producing O-demethylation (Caraco et al. 1997).
Peroxisome proliferators. It is well established that several agents that cause
peroxisome proliferation in the liver, such as clo® brate and nafenopin, are potent
hepatocarcinogens and inducers of the CYP4A subfamily forms in rodents (Johnson
et al. 1996). However, humans are resistant to the peroxisome proliferating eå ects
produced by this class of compounds, and they are not considered to pose a
hepatocarcinogenic hazard (Bentley et al. 1993, Lake 1995). Since members in the
CYP4A subfamily participate in the maintenance of tissue homeostasis, including
regulation of blood ¯ ow in the kidney and brain (Simpson 1997), any changes in the
activities of CYP4A enzymes might theoretically aå ect these vital functions.
Evidence for this, however, is lacking in humans. Due to the very low abundance of
CYP4A protein in the human liver and paucity of relevant drug substrates, its role
in the overall pharmacokinetics of commonly used drugs must be considered as
negligible.
Consequences of enzyme induction
For drugs that are active in their parent form, induction may increase the drug’ s
elimination and decrease its pharmacological eå ect. For prodrugs, compounds that
require metabolic activation and whose eå ects are produced by the active
metabolites, enhanced pharmacodynamic eå ects may be expected. The toxicological
implications of enzyme induction have been discussed by Park et al. (1996).
A good example of an adverse consequence due to enzyme induction is the
increased toxicity of paracetamol (acetaminophen). Long-term consumption of
alcohol is associated with liver damage from therapeutic doses ( ! 4 g } day) of
paracetamol (Nelson 1990). As illustrated in ® gure 2, CYP2E1 is the major enzyme
in converting paracetamol to the reactive intermediate, N-acetyl-p-amino-
benzoquinone (NAPQI). Thus, conditions which increase the activity of CYP2E1
may sensitise an individual to the toxic e å ects of paracetamol. This has been shown
to occur in man and experimental animals, particularly associated with chronic
ethanol exposure (Zimmerman and Maddrey 1995). In accordance with this, a
P450 inhibition and induction in man 1241
recently developed CYP2E1 knock-out mouse strain (Cyp2e1 Õ /Õ ) was shown to be
considerably more resistant to the hepatotoxic eå ects of paracetamol than the
corresponding wild-type mice (Lee et al. 1996). These ® ndings would implicate a
dominant role for CYP2E1 in ethanol-caused paracetamol toxicity, but recent
evidence that ethanol also induces CYP3A forms (Kostrubsky et al. 1995) and the
ability of CYP3A inhibitors to prevent ethanol-induced liver damage in rat
(Kostrubsky et al. 1997) suggest that CYP3 enzymes may also mediate paracetamol
activation to toxic intermediates.
Research needs and future trends
This review is just one attempt to treat (semi)quantitatively in vitro ± in vivo
extrapolation of drug metabolism and interactions, and future studies are described
below.
For obvious reasons, human liver microsomes are the gold standard for in vitro
studies. However, because of practical and ethical reasons, their availability is
limited and we need a renewable source of human enzymes, such as recombinant
expressed enzymes in suitable host cells. For them to be useful and reliable, we need
more comparative studies in which human liver microsomal and recombinant
enzymes are being characterized at the same time and under the same experimental
conditions.
The large variability in human CYP-associated activities needs to be dealt with
in a meaningful way. The ® rst obvious task would be to evaluate to what extent
sometimes extreme variations seen in original studies are due to technical reasons
and } or to ` genuine ’ biological reasons. This type of evaluation has not been
performed to any considerable extent. After this analysis, calculations should be
performed with diå erent, even extreme, scenarios in mind to get some information
about rare deviant possibilities.
For in vitro ± in vivo extrapolation, we need more information about factors that
determine the concentration of a drug at the site of an enzyme. Currently we have to
resort in most cases to plasma concentrations, or free concentrations after allowing
for plasma protein binding, but more research is required to de® ne hepatic uptake
and persistence, and non-metabolic processes in the liver and extrahepatic tissues
aå ecting the concentrations of compounds under study.
A thorough analysis and identi® cation of what are the suæ cient parameters for
drug metabolism and elimination in vivo remains to be performed. Formation
clearances of important metabolites together with knowledge of non-metabolic
absorption characteristics and clearance(s) might be appropriate and suæ cient
knowledge for attempts to perform in vitro ± in vivo extrapolations. Interindividual
variability should also be taken into account.
However, identifying relevant parameters to describe in vivo changes in drug
clearance as a consequence of interaction is only a beginning. From the clinical
standpoint, it is of importance to judge whether the change is actually clinically
signi® cant. This is not an easy task, because at ® rst glance, every drug is diå erent in
terms of frequency, severity and dose-dependency of side eå ects, which determine
the clinical signi® cance. It is diæ cult with our current state of knowledge to identify
quantitative rules or classi® cations to con® dently predict whether or not a given
interaction would lead to a clinically signi® cant outcome.
1242 O. Pelkonen et al.
Acknow ledgem ents
This review was written to contribute to the goals of the COST Action B1. The
work in the authors’ laboratory has been supported by The Academy of Finland
Medical Research Council (Contract Nos 1051029 and 34555), by the Biomed1
project and by the Biomed2 project EUROCYP.
References
A c o c e l l a , G., 1978, Clinical pharmacokinetics of rifampicin. Clinical Pharmacokinetics, 3, 108± 127.A h o n e n , J., O l k k o l a , K. T. and N e u v o n e n , P. J., 1997, Eå ect of route administration of ¯ uconazole on
the interaction between ¯ uconazole and midazolam. European Journal of Clinical Pharmacology,51, 415± 420.
A l v a n , G., B e c h t e l , P., I s e l i u s , L. and G u n d e r t -R e m y , U., 1990, The hydroxylation polymorphismsof debrisoquine and mephenytoin in European populations. European Journal of Clinical
Pharmacology, 39 , 533± 537.A m e e r , B. and W e i n t r a u b , R. A., 1997, Drug interactions with grapefruit juice. Clinical Pharmaco-
kinetics, 33 , 103± 121.A n d e r s s o n , T., B e r g s t r a n d , R., C e d e r b e r g , C., E r i k s s o n , S., L a g e r s t r o m , P. and S k a n b e r g , I., 1991,
Omeprazole treatment does not aå ect the metabolism of caå eine. Gastroentero logy, 101 , 943± 947.A n d e r s s o n , T., M i n e r s , J. O., V e r o n e s e , M. E., T a s s a n e e y a k u l , W., T a s s a n e e y a k u l , W., M e y e r ,
U. A. and B i r k e t t , D. J., 1993, Identi® cation of human liver cytochrome P450 isoformsmediating omeprazole metabolism. British Journal of Clinical Pharmacology, 36, 521± 530.
A o y a m a , T., Y a m a n o , S., G u z e l i a n , P. S., G e l b o i n , H. V. and G o n z a l e z , F. J., 1990, Five of 12 formsof vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate a¯ atoxin B
".
Proceedings of the National Academy of Sciences, USA 87, 4790± 4793.B a c i e w i c z , A. M. and S e l f , T. H., 1984, Rifampicin drug interactions. Archives of Internal Medicine,
144, 1667± 1671.B a c i e w i c z , A. M., S e l f , T. H. and B e k e m e y e r , W. B., 1987, Update on rifampicin drug interactions.
Archives of Internal Medicine, 147, 565± 568.B a c k m a n , J. T., O l k k o l a , K. T., A r a n k o , K., H i m b e r g , J. J. and N e u v o n e n , P. J., 1994, Dose of
midazolam should be reduced during diltiazem and verapamil treatments. British Journal ofClinical Pharmacology, 37 , 221± 225.
B a c k m a n , J. T., O l k k o l a , K. T. and N e u v o n e n , P. J., 1995, Azithromycin does not increase plasmaconcentrations of oral midazolam. International Journal of Pharmacology and Therapeutics, 33,
356± 359.B a c k m a n , J. T., O l k k o l a , K. T. and N e u v o n e n , P. J., 1996, Rifampin drastically reduces plasma
concentrations and eå ects of oral midazolam. Clinical Pharmacology and Therapeutics, 59, 7± 13.B a i l e y , D. G., S p e n c e , J. D., M u n o z , C. and A r n o l d , J. M., 1991, Interaction of citrus juices with
felodipine and nifedipine. Lancet, 337, 268± 269.B a j p a i , M., R o s k o s , L. K., S h e n , D. D. and L e v y , R. H., 1996, Roles of cytochrome P4502C9 and
cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.Drug Metabolism and Disposition, 24 , 1401± 1403.
B a r w i c k , J. L., Q u a t t r o c h i , L. C., M i l l s , A. S., P o t e n z a , C., T u k e y , R. H. and G u z e l i a n , P. S.,1996, Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional
activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures ofadult rat and rabbit hepatocytes. Molecular Pharmacology, 50, 10± 16.
B a u m a n n , P. and L a r s e n , F., 1995, The pharmacokinetics of citalopram. Reviews in ContemporaryPharmacotherapeutics, 6, 287± 295.
B e n t l e y , P., C a l d e r , I., E l c o m b e , C., G r a s s o , P., S t r i n g e r , D. and W i e g a n d , H.-J., 1993, Hepaticperoxisome proliferation in rodents and its signi® cance for humans. Food and Chemical Toxicology,31, 857± 907.
B e r t i l s s o n , L., T y b r i n g , G., W i d e ! n , J., C h a n g , M. and T o m s o n , T., 1997, Carbamazepine treatment
induces the CYP3A4 catalysed sulphoxation of omeprazole, but has no or less eå ect onhydroxylation via CYP2C19. British Journal of Clinical Pharmacology, 44, 186± 189.
B i r k e t t , D. J., M a c K e n z i e , P. I., V e r o n e s e , M. E. and M i n e r s , J. O., 1993, In vitro approaches canpredict human drug metabolism. Trends in Pharmacological Science, 14 , 292± 294.
B i r k e t t , D. J., R e e s , D., A n d e r s s o n , T., G o n z a l e z , F. J., M i n e r s , J. O. and V e r o n e s e , M. E., 1994, Invitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A
isoforms as well as by S-mephenytoin hydroxylase. British Journal of Clinical Pharmacology, 37,413± 420.
B l a c k , D. J., K u n z e , K. L., W i e n k e r s , L. C., G i d a l , B. E., S e a t o n , T. L., M c D o n n e l l , N. D.,E v a n s , J. S., B a u w e n s , J. E. and T r a g e r , W. F., 1996, Warfarin-¯ uconazole II. A metabolically
based drug interaction : in vivo studies. Drug Metabolism and Disposition, 24 , 422± 428.
P450 inhibition and induction in man 1243
B o o b i s , A. R., 1995, Prediction of inhibitory drug± drug interactions by studies in vitro. In G. M. Paci® ci
and G. N. Fracchia (eds), (Luxembourg : Oæ ce for Oæ cial Publications of the EuropeanCommunities), pp. 513± 539.
B o o b i s , A. R. and D a v i e s , D. S., 1984, Human cytochromes. Xenobiotica , 14, 151± 185.B o o b i s , A. R., B r o d i e , J. J., K a h n , G. C., T o v e r u d , E. L., B l a i r , I. A., M u r r a y , S. and D a v i e s , D. S.,
1981, Comparison of the in vivo and in vitro rates of formation of the three main oxidativemetabolites of antipyrine in man. British Journal of Clinical Pharmacology, 12, 771± 777.
B o u r r i e , M., M e u n i e r , V., B e r g e r , Y. and F a b r e , G., 1996, Cytochrome P450 isoform inhibitors as atool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of
Pharmacology and Experimental Therapeutics, 277, 321± 332.B r i a n , W. R., S r i v a s t a v a , P. K., U m b e n h a u e r , D. R., L l o y d , R. S. and G u e n g e r i c h , F. P., 1989,
Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity inSaccharomyces cerevisiae. Biochemistry , 28, 4993± 4999.
B r o d i e , M. J. and D i c h t e r , M. A., 1996, Antiepileptic drugs. New England Journal of Medicine, 334,168± 175.
B r o s e n , K., 1993, The pharmacogenetics of the selective serotonin reuptake inhibitors. ClinicalInvestigator, 71, 1002± 1009.
B r o s e n , K., 1996, Are pharmacokinetic drug interactions with the SSRIs an issue ? International Journalof Clinical Psychopharmacology, 11, 23± 27.
B r o s e n , K. and G r a m , L. F., 1989, Clinical signi® cance of the sparteine } debrisoquine oxidationpolymorphism. European Journal of Clinical Pharmacology, 36, 537± 547.
B r o s e n , K., S k j e l b o , E., R a s m u s s e n , B. B., P o u l s e n , H. E. and L o f t , S., 1993, Fluvoxamine is a potentinhibitor of cytochrome P4501A2. Biochemical Pharmacology, 45 , 1211± 1214.
B u c h t h a l , J., G r u n d , K. E., B u c h m a n n , A., S c h r e n k , D., B e a u n e , P. and B o c k , K. W., 1995,Induction of cytochrome P450IA by smoking or omeprazole in comparison with UDP-
glucuronosyltransferase in biopsies of human duodenal mucosa. European Journal of ClinicalPharmacology, 47 , 431± 435.
B u r k e , M. D., P r o u g h , R. A. and M a y e r , R. T., 1977, Characteristics of a microsomal cytochrome P-448-mediated reaction : ethoxyresoru® n O-deethylation. Drug Metabolism and Disposition, 5, 1± 8.
B u t l e r , M. A., I w a s a k i , M., G u e n g e r i c h , F. P. and K a d l u b a r , F. F., 1989, Human cytochrome P-450
PA(P-450IA2), the penacetin O-deetylase, is primarily responsible for hepatic 3-demethylation
of caå eine and N-oxidation of carcinogenic arylamines. Proceedings of the National Academy ofSciences, USA, 86, 7696± 7700.
B u t l e r , M. A., L a n g , N. P., Y o u n g , J. F., C a p o r a s o , N. E., V i n e i s , P., H a y e s , R. B., T e i t e l , C. H.,M a s s e n g i l l , J. P., L a w s o n , M. F. and K a d l u b a r , F. F., 1992, Determination of CYP1A2 and
acetyltransferase 2 phenotypes in human populations by analysis of caå eine urinary metabolites.Pharmacogenetics, 2, 116± 127.
C a r a c o , Y., S h e l l e r , J. and W o o d , A. J. J., 1997, Pharmacogenetic determinants of codeine inductionby rifampin : The impact on codeine’ s respiratory, psychomotor and miotic eå ects. Journal of
Pharmacology and Experimental Therapeutics, 281, 330± 336.C a r r o c c i o , A., W u , D. and C e d e r b a u m , A. I., 1994, Ethanol increases content and activity of human
cytochrome P4502E1 in a transduced HepG2 cell line. Biochemical and Biophysical ResearchCommunications, 203 , 727± 733.
C h a n g , T. K. H., Y u , L., M a u r e l , P. and W a x m a n , D. J., 1997, Enhanced cyclophosphamide andifosfamide activation in primary human hepatocyte cultures : response to cytochrome P-450
inducers and autoinduction by oxazaphosphorines. Cancer Research, 57 , 1946± 1954.C h i b a , K., M a n a b e , K., K o b a y a s h i , K., T a k a y a m a , Y., T a n i , M. and I s h i z a k i , T., 1993, Development
and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in humanliver microsomes. European Journal of Clinical Pharmacology, 44, 559± 562.
C h i e n , J. Y., P e t e r , R. M., N o l a n , C. M., W a r t e l l , C., S l a t t e r y , J. T., N e l s o n , S. D., C a r i t h e r s ,R. L. and T h u m m e l , K. E., 1997, In¯ uence of polymorphic N-acetyltransferase phenotype on the
inhibition and induction of acetaminophen bioactivation with long-term isoniazid. ClinicalPharmacology and Therapeutics, 61, 24± 34.
C h i n g , M. S., B l a k e , C. L., G h a b r i a l , H., E l l i s , S. W., L e n n a r d , M. S., T u c k e r , G. T. andS m a l l w o o d , R. A., 1995, Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine,
quinidine, and its metabolites. Biochemical Pharmacology, 50, 833± 837.C h o l e r t o n , S., D a l y , A. K. and I d l e , J. R., 1992, The role of individual human cytochromes P450 in
drug metabolism and clinical response. Trends in Pharmacological Science, 13, 434± 439.C h r i s t i a n s , U. and S e w i n g , K.-F., 1993, Cyclosporin metabolism in transplant patients. Pharmacology
and Therapeutics, 57 , 291± 345.C l a r k e , S. E., A y r t o n , A. D. and C h e n e r y , R. J., 1994, Characterization of the inhibition of P4501A2
by furafylline. Xenobiotica , 24, 517± 526.C o n n e l l y , J. F., 1993, Vigabatrin. Annals of Pharmacotherapy, 27, 197± 204.
1244 O. Pelkonen et al.
C r o f t s , F., T a i o l i , E., T r a c h m a n , J., C o s m a , G. N., C u r r i e , D., T o n i o l o , P. and G a r t e , S. J., 1994,
Functional signi® cance of diå erent human CYP1A1 genotypes. Carcinogenesis, 15, 2961± 2963.C u r i -P e d r o s a , R., D a u j a t , M., P i c h a r d , L., O u r l i n , J. C., C l a i r , P., G e r v o t , L., L e s c a , P.,
D o m e r g u e , J., J o y e u x , H., F o u r t a n i e r , G. and M a u r e l , P., 1994, Omeprazole and lansoprazoleare mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. Journal of
Pharmacology and Experimental Therapeutics, 269, 384.D a l e t -B e l u c h e , I., B o u l e n c , X., F a b r e , G., M a u r e l , P. and B o n f i l s , C., 1992, Puri® cation of two
cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon,Papio papio) liver microsomes. Cross reactivity with human forms. European Journal of
Biochemistry, 204 , 641± 648.D a u j a t , M., C h a r r a s s e , S., F a b r e , I., L e s c a , P., J o u n a i d i , Y., L a r r o q u e , C., P o e l l i n g e r , L. and
M a u r e l , P., 1996, Induction of CYP1A1 gene by benzimidazole derivatives during Caco-2 celldiå erentiation. Evidence for an aryl-hydrocarbon receptor-mediated mechanism. European
Journal of Biochemistry, 237, 642± 652.D a u j a t , M., P e r y t , B., L e s c a , P., F o u r t a n i e r , G., D o m e r g u e , J. and M a u r e l , P., 1992, Omeprazole,
an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor. Biochemical andBiophysical Research Communications, 188 , 820± 825.
D i a z , D., F a b r e , I., D a u j a t , M., F a b r e , G., J o y e u x , H., B o r i e s , P., M i c h e l , H. and M a u r e l , P., 1990,The gastric antisecretory drug omeprazole is an aryl hydrocarbon-like inducer of human hepatic
cytochrome P450. Gastroenterology, 99, 737± 747.D i s t l e r a t h , L. M., R e i l l y , P. E. B., M a r t i n , M. V., D a v i s , G. G., W i l k i n s o n , G. R. and
G u e n g e r i c h , F. P., 1985, Puri® cation and characterization of human liver cytochromes P-450involved in debrisoquine 4-hydroxylation and phenacetin O-deetylation, two prototypes for
genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry, 260,9057± 9067.
D o l l e r y , C., B o o b i s , A. R., B u r l e y , D., D a v i e s , D. M., D a v i e s , D. S., H a r r i s o n , P. I., O r m e , M. L.,P a r k , B. K. and G o l d b e r g , L. I., 1991, Therapeutic Drugs (Edinburgh : Churchill Livingstone).
D o n a t o , M. T., C a s t e l l , J. V. and G o m e z -L e c h o n , M. J., 1995, Eå ect of model inducers oncytochrome P450 activities of human hepatocytes in primary culture. Drug Metabolism and
Disposition , 23, 553± 558.D u n d e e , J. W., H a l l i d a y , N. J., H a r p e r , K. W. and B r o g d e n , R. N., 1984, Midazolam. A review of its
pharmacological properties and therapeutic use. Drugs, 28 , 519± 543.D z e l e t o v i c , N., M c G u i r e , J., D a u j a t , M., T h o l a n d e r , J., E m a , M., F u j i i -K u r i y a m a , Y., B e r g m a n ,
J., M a u r e l , P. and P o e l l i n g e r , L., 1997, Regulation of dioxin receptor function by omeprazole.Journal of Biological Chemistry, 272 , 12705± 12713.
E i c h e l b a u m , M., S p a n n b r u c k e r , N., S t e i n c k e , B. and D e n g l e r , H. J., 1979, Defective N-oxidation ofsparteine in man : a new pharmacogenetic defect. European Journal of Clinical Pharmacology, 16,
183± 187.E k i n s , S., M a $ e n p a $ a $ , J. and W r i g h t o n , S. A., 1998, In vitro metabolism : subcellular fractions. In T. F.
Woolf (ed.), Handbook of Drug Metabolism (New York : Marcel Dekker) (in press).E l i a s s o n , E., M k r t c h i a n , S. and I n g e l m a n -S u n d b e r g , M., 1992, Hormone-, and substrate-regulated
intracellular degradation of CYP2E1 involving MgATP-activated rapid proteolysis in theendoplasmic reticulum membranes. Journal of Biological Chemistry, 267, 15765± 15769.
E n g e l , G., H o f m a n n , U., H e i d e m a n n , H., C o s m e , J. and E i c h e l b a u m , M., 1996, Antipyrine as a probefor human oxidative drug metabolism : identi® cation of the cytochrome P450 enzymes catalyzing
4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clinical Phar-macology and Therapeutics, 59, 613± 623.
F i s c h e r , V., V o g e l s , B., M a u r e r , G. and T y n e s , R. E., 1992, The antipsychotic clozapine is metabolizedby the polymorphic human microsomal and recombinant cytochrome P450 2D6. Journal of
Pharmacology and Experimental Therapeutics, 260, 1355± 1360.F r e e m a n , D. J., L a u p a c i s , A., K e o w n , P. A., S t r i l l e r , C. R. and C a r r u t h e r s , S. G., 1984, Evaluation
of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. British Journalof Clinical Pharmacology, 18, 887± 893.
G a l b r a i t h , R. A. and M i c h n o v i c z , J. J., 1993, Omeprazole fails to alter the cytochrome P450-dependent 2-hydroxylation of estradiol in male volunteers. Pharmacology, 47 , 8 ± 12.
G a s c o n , M.-P. and D a y e r , P., 1991, In vitro forecasting of drugs which may interfere with thebiotransformation of midazolam. European Journal of Clinical Pharmacology, 41, 573± 578.
G e d , C., R o u i l l o n , J. M., P i c h a r d , L., C o m b a l b e r t , J., B r e s s o t , N., B o r i e s , P., M i c h e l , H., B e a u n e ,P. and M a u r e l , P., 1989, The increase in urinary excretion of 6b-hydroxycortisol as a marker of
human hepatic cytochrome P450IIIA induction. British Journal of Clinical Pharmacology, 28,373± 387.
G e d , C., U m b e n h a u e r , D. R., B e l l e w , T. M., B o r k , R. W., S r i v a s t a v a , P. K., S h i n r i k i , N., L l o y d ,R. S. and G u e n g e r i c h , F. P., 1988, Characterization of cDNAs, mRNAs, and proteins related to
human liver microsomal cytochrome P-450 (S)-mephenytoin 4´-hydroxylase. Biochemistry, 27,6929± 6940.
P450 inhibition and induction in man 1245
G h o s a l , A., S a t o h , H., T h o m a s , P. E., B u s h , E. and M o o r e , D., 1996, Inhibition and kinetics of
cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed humancytochrome P450. Drug Metabolism and Disposition, 24, 940± 947.
G i r r e , C., L u c a s , D., H i s p a r d , E., M e n e z , C., D a l l y , S. and M e n e z , J. F., 1994, Assessment ofcytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics.
Biochemical Pharmacology, 47, 1503± 1508.G o a , K. L., R o s s , S. R. and C h r i s p , P., 1993, Lamotrigine. A review of its pharmacological properties
and clinical eæ cacy in epilepsy. Drugs, 46, 152± 176.G o a , K. L. and S o r k i n , E. M., 1993, Gabapentin. Drugs, 46, 409± 427.
G o l d b e r g , M. J., R i n g , B., D e s a n t e , K., C e r i m e l e , B., H a t c h e r , B., S i d e s , G. and W r i g h t o n , S.,1996, Eå ect of dirithromycin on human CYP3A in vitro and on pharmacokinetics and
pharmacodynamics of terfenadine in vivo. Journal of Clinical Pharmacology, 36, 1154± 1160.G o l d s t e i n , J. A. and D e M o r a i s , S. M. F., 1994, Biochemistry and molecular biology of the human
CYP2C subfamily. Pharmacogenetics, 4, 285± 299.G o n z a l e z , F. J., 1990, Molecular genetics of the P-450 superfamily. Pharmacology and Therapeutics, 45,
1 ± 38.G o n z a l e z , F. J., 1992, Human cytochromes P450 : problems and prospects. Trends in Pharmacological
Science, 13 , 346± 352.G o r s k i , J. C., H a l l , S. D., J o n e s , D. R., V a n d e n b r a n d e n , M. and W r i g h t o n , S. A., 1994,
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A(CYP3A) subfamily. Biochemical Pharmacology, 47, 1643± 1653.
G r e u e t , J., P i c h a r d , L., B o n f i l s , C., D o m e r g u e , J. and M a u r e l , P., 1996, The fetal speci® c geneCYP3A7 is inducible by rifampicin in adult human hepatocytes in primary culture. Biochemical
and Biophysical Research Communications, 225, 689± 694.G u e n g e r i c h , F. P., 1990, Mechanism-based inactivation of human liver cytochrome P-450 IIIA4 by
gestodene. Chemical Research in Toxicology, 3, 363± 371.G u e n g e r i c h , F. P., 1992, Cytochrome P450 : advances and prospects. FASEB Journal, 6 , 667± 668.
G u e n g e r i c h , F. P., 1993, Bioactivation and detoxication of toxic and carcinogenic chemicals. DrugMetabolism and Disposition, 21, 1± 6.
G u e n g e r i c h , F. P., 1994, Catalytic selectivity of human cytochrome P450 enzymes : relevance to drugmetabolism and toxicity. Toxicology Letters, 70 , 133± 138.
G u e n g e r i c h , F. P., 1995a, Cytochromes P450 of human liver. Classi® cation and activity pro® les of themajor enzymes. In G. M. Paci® ci and G. N. Fracchia (eds), Advances in Drug Metabolism in Man
(Luxembourg : European Commission, Oæ ce for the Oæ cial Publications of the EuropeanCommunities), pp. 179± 231.
G u e n g e r i c h , F. P., 1995b, Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (eds),Cytochrome P450: Structure , Mechanism, and Biochemistry (New York : Plenum), pp. 473± 536.
G u e n g e r i c h , F. P., M a r t i n , M. V., B e a u n e , P. H., K r e m e r s , P., W o l f f , T. and W a x m a n , D. J., 1986,Characterization of rat and human liver microsomal cytochrome P-450 forms involved in
nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. Journalof Biological Chemistry, 261, 5051± 5060.
G u e n g e r i c h , F. P. and S h i m a d a , T., 1991, Oxidation of toxic and carcinogenic chemicals by humancytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391± 407.
H a k k o l a , J., P a s a n e n , M., P e l k o n e n , O., H u k k a n e n , J., E v i s a l m i , S., A n t t i l a , S., R a n e , A.,M a $ n t y l a $ , M., P u r k u n e n , R., S a a r i k o s k i , S., T o o m i n g , M. and R a u n i o , H., 1997, Expression
of CYP1B1 in human adult and fetal tissues and diå erential inducibility of CYP1B1 and CYP1A1by Ah receptor ligands in human placenta and cultured cells. Carcinogenesis, 18 , 391± 397.
H a l l i d a y , R. C., J o n e s , B. C., S m i t h , D. A., K i t t e r i n g h a m , N. R. and P a r k , B. K., 1995, Aninvestigation of the interaction between halofantrine, CYP2D6 and CYP3A4 : studies with human
liver microsomes and heterologous enzyme expression systems. British Journal of ClinicalPharmacology, 40 , 369± 378.
H a m m a n , M. A., T h o m p s o n , G. A. and H a l l , S. D., 1997, Regioselective and stereoselectivemetabolism of ibuprofen by human cytochrome P450 2C. Biochemical Pharmacology, 54, 33± 41.
H a n k i n s o n , O., 1995, The aryl hydrocarbon receptor complex. Annual Reviews of Pharmacology andToxicology, 35, 307± 340.
H a r d m a n , J. G., L i m b i r d , L. E., M o l i n o f f , P. B., R u d d o n , R. W. and G i l m a n , A. G., 1996, Goodman& Gilman ’ s The Pharmacological Basis of Therapeutics (New York : McGraw-Hill).
H a r r i s , J. W., R a h m a n , A., K i n , B.-R., G u e n g e r i c h , F. P. and C o l l i n s , J. M., 1994, Metabolism oftaxol by human hepatic microsomes and liver slices : participation of cytochrome P450 3A4 and
an unknown P450 enzyme. Cancer Research , 54 , 4026± 4035.H a s h i m o t o , H., T o i d e , K., K i t a m u r a , R., F u j i t a , M., T a g a w a , S., I t o h , S. and K a m a t a k i , T., 1993,
Gene structure of CYP3A4, an adult-speci® c form of cytochrome P450 in human livers, and itstranscriptional control. European Journal of Biochemistry, 218 , 585± 595.
H e b e r t , M. F., R o b e r t s , J. P., P r u e k s a r i t a n o n t , T. and B e n e t , L. Z., 1992, Bioavailability of
1246 O. Pelkonen et al.
cyclosporine with concomitant rifampin administration is markedly less than predicted by
hepatic enzyme induction. Clinical Pharmacology and Therapeutics, 52, 453± 457.H u , Y., O s c a r s o n , M., J o h a n s s o n , I., Y u e , Q.-Y., D a h l , M.-L., T a b o n e , M., A r i n c o , S., A l b a n o , E.
and I n g e l m a n -S u n d b e r g , M., 1997, Genetic polymorphism of human CYP2E1 : Charac-terization of two variant alleles. Molecular Pharmacology, 51, 370± 376.
I s o j a $ r v i , J. I. T., P a k a r i n e n , A., R a u t i o , A., P e l k o n e n , O. and M y l l y l a $ , V. V., 1994, Liver enzymeinduction and serum lipid levels after replacement of carbamazepine with oxcarbazepine.
Epilepsia, 35 , 1217± 1220.J a c q u e t , M., L a m b e r t , V., B a u d o u x , E., M u l l e r , M., K r e m e r s , P. and G i e l e n , J., 1996, Correlation
between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence. European Journalof Cancer, 32A , 1701± 1706.
J e n s e n , P. K., S a a n o , V., H a r i n g , P., S v e n s t r u p , B. and M e n g e , G. P., 1992, Possible interactionbetween oxcarbazepine and an oral contraceptive. Epilepsia, 33 , 1149± 1152.
J e p p e s e n , U., G r a m , L. F., V i s t i s e n , K., L o f t , S., P o u l s e n , H. E. and B r o s e n , K., 1996, Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, ¯ uoxetine, ¯ uvoxamine
and paroxetine. European Journal of Clinical Pharmacology, 51 , 73± 78.J e p p e s e n , U., R a s m u s s e n , B. B. and B r o s e n , K., 1997, The CYP2C19 catalyzed bioactivation of
proguanil is abolished during ¯ uvoxamine intake. European Journal of Clinical Pharmacology, 52,A134.
J o h a n s s o n , I., L u n d q v i s t , E., B e r t i l s s o n , L., D a h l , M.-L., S j o $ q v i s t , F. and I n g e l m a n -S u n d b e r g ,M., 1993, Inherited ampli® cation of an active gene in the cytochrome P450 CYP2D locus as a
cause of ultrarapid metabolism of debrisoquine. Proceedings of the National Academy of Sciences,USA, 90, 11825± 11829.
J o h n s o n , E. F., P a l m e r , C. N. A., G r i f f i n , K. J. and H s u , M.-H., 1996, Role of the peroxisomeproliferator-activated receptor in cytochrome P450 4A gene regulation. FASEB Journal, 10,
1241± 1248.J o h n s o n , E. F., S c h w a b , G. E. and V i c k e r y , L. E., 1988, Positive eå ectors of the binding of an active
site-directed amino steroid to rabbit cytochrome P-450 3c. Journal of Biological Chemistry, 263,17672± 17677.
J u r i m a -R o m e t , M., C r a w f o r d , K., C y r , T. and I n a b a , T., 1994, Terfenadine metabolism in humanliver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metabolism and
Disposition , 22, 849± 857.K a m i n s k y , L. S., 1989, Warfarin as a probe of cytochromes P-450 function. Drug Metabolism Reviews,
20, 479± 487.K a m i n s k y , L. S. and F a s c o , M. J., 1992, Small intestinal cytochromes P450. Critical Review in
Toxicology, 21, 407± 422.K a m i n s k y , L. S. and Z h a n g , Z.-Y., 1997, Human P450 metabolism of warfarin. Pharmacology and
Therapeutics, 73 , 67± 74.K a s h f i , K., M c D o u g a l l , C. J. and D a n n e n b e r g , A. J., 1995, Comparative eå ects of omeprazole on
xenobiotic metabolizing enzymes in the rat and human. Clinical Pharmacology and Therapeutics,58, 625± 630.
K a t o , R., Y a m a z o e , Y. and Y a s u m o r i , T., 1992, Polymorphism in stereoselective hydroxylations ofmephenytoin and hexobarbital by Japanese liver samples in relation to cytochrome P-450 human-
2 (IIC9). Xenobiotica , 22, 1083± 1092.K a w a j i r i , K., N a k a c h i , K., I m a i , K., W a t a n a b e , J. and H a y a h s i , S., 1993, The CYP1A1 gene and
cancer susceptibility . Critical Reviews in Oncology and Hematology, 14, 77± 87.K a $ l v i a $ i n e n , R., K e r a $ n e n , T. and R i e k k i n e n , P. J., 1993, Place of newer antiepileptic drugs in the
treatment of epilepsy. Drugs, 46, 1009± 1024.K e r r , B. M., T h u m m e l , K. E., W u r d e n , C. J., K l e i n , S. M., K r o e t z , D. L., G o n z a l e z , F. J. and
L e v y , R. H., 1994, Human liver carbamazepine metabolism ; role of CYP3A4 and CYP2C8 in10,11-epoxide formation. Biochemical Pharmacology, 47, 1969± 1979.
K e r r y , N. L., S o m o g y i , A. A., B o c h n e r , F. and M i k u s , G., 1994, The role of CYP2D6 in primary andsecondary oxidative metabolism of dextromethorphan : in vitro studies using human liver
microsomes. British Journal of Clinical Pharmacology, 38 , 243± 248.K i k u c h i , H., H o s s a i n , A., S a g a m i , I., I k a w a , S. and W a t a n a b e , M., 1995, Diå erent inducibility of
cytochrome P-4501A1 mRNA of human and mouse by omeprazole in cultured cells. Archives ofBiochemistry and Biophysics, 316 , 649± 652.
K i m , R. B., O’ S h e a , D. and W i l k i n s o n , G. R., 1995, Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms.
Clinical Pharmacology and Therapeutics, 57 , 645± 655.K i v i s t o $ , K. T. and K r o e m e r , H. K., 1997, Use of probe drugs as predictors of drug metabolism in
humans. Journal of Clinical Pharmacology, 37, 40S± 48S.K n o d e l l , R. G., B r o w n e , D. G., G w o z d z , G. P., B r i a n , W. R. and G u e n g e r i c h , F. P., 1991,
Diå erential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastro-enterology, 101, 1680± 1691.
P450 inhibition and induction in man 1247
K n o d e l l , R. G., H a l l , S. D., W i l k i n s o n , G. R. and G u e n g e r i c h , F. P., 1987, Hepatic metabolism of
tolbutamide : characterization of the forms of cytochrome P-450 involved in methyl hydroxylationand relationship to in vivo disposition. Journal of Pharmacology and Experimental Therapeutics,241, 1112± 1119.
K o b a y a s h i , K., C h i b a , K., Y a g i , T., S h i m a d a , N., T a n i g u c h i , T., H o r i e , T., T a n i , M., Y a m a m o t o ,
T., I s h i z a k i , T. and K u r o i w a , Y., 1997, Identi® cation of cytochrome P450 isoforms involved incitalopram N-demethylation by human liver microsomes. Journal of Pharmacology and Ex-
perimental Therapeutics, 280, 927± 933.K o c a r e k , T. A., S c h u e t z , E. G., S t r o m , S. C., F i s h e r , R. A. and G u z e l i a n , P. S., 1995, Comparative
analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and humanhepatocytes. Drug Metabolism and Disposition, 23 , 415± 421.
K o l a r s , J. C., L o w n , K. S., S c h m i e d l i n -R e n , P., G h o s h , M., F a n g , C., W r i g h t o n , S. A., M e r i o n ,R. M., and W a t k i n s , P. B., 1994, CYP3A gene expression in human gut epithelium. Pharmaco-
genetics, 4, 247± 259.K o l a r s , J. C., S c h m i e d l i n -R e n , P., S c h u e t z , J. D., F a n g , C. and W a t k i n s , P. B., 1992, Identi® cation
of rifampicin-inducible P450IIA4 (CYP3A4) in human small bowel enterocytes. Journal ofClinical Investigation, 90, 1871± 1878.
K o l e y , A. P., B u t e r s , J. T. M., R o b i n s o n , R. C., M a r k o w i t z , A. and F r i e d m a n , F. K., 1997,Diå erential mechanisms of cytochrome P450 inhibition and activation by a-naphtho¯ avone.
Journal of Biological Chemistry, 272 , 3149± 3152.K o o p , D. R., 1992, Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB Journal, 6,
724± 730.K o s t r u b s k y , V. E., S t r o m , S. C., W o o d , S. G., W r i g h t o n , S. A., S i n c l a i r , P. R. and S i n c l a i r , J. F.,
1995, Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of humanhepatocytes. Archives of Biochemistry and Biophysics, 322, 516± 520.
K o s t r u b s k y , V. E., S z a k a c s , J. G., J e f f e r y , E. H., W o o d , S. G., B e m e n t , W. J., W r i g h t o n , S. A.,S i n c l a i r , P. R. and S i n c l a i r , J. F., 1997, Role of CYP3A in ethanol-mediated increases in
acetaminophen hepatotoxicity. Toxicology and Applied Pharmacology, 143 , 315± 323.K r o n b a c h , T., M a t h y s , D., U m e n o , M., G o n z a l e z , F. J. and M e y e r , U. A., 1989, Oxidation of
midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36,89± 96.
K u n z e , K. L. and T r a g e r , W. F., 1996, Warfarin-¯ uconazole III. A rational approach to managementof a metabolically based drug interaction. Drug Metabolism and Disposition, 24, 429± 435.
K u n z e , K. L., W i e n k e r s , L. C., T h u m m e l , K. E. and T r a g e r , W. F., 1996, Warfarin-¯ uconazole I.Inhibition of the human cytochrome P450-dependent metabolism of warfarin by ¯ uconazole : in
vitro studies. Drug Metabolism and Disposition, 24, 414± 421.K u p f e r s c h m i d t , H. H. T., H a , H. R., Z i e g l e r , W. H., M e i e r , P. J. and K r a $ h e n b u h l , S., 1995,
Interaction between grape fruit juice and midazolam in humans. Clinical Pharmacology andTherapeutics, 58 , 20± 28.
L a k e , B. G., 1995, Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs andchemicals. Annual Reviews of Pharmacology and Toxicology, 35 , 483± 507.
L a m , Y. W. F., 1988, Stereoselectivity : an issue of signi® cant importance in clinical pharmacology.Pharmacotherapy, 8, 147± 157.
L a n d i , M. T., B e r t a z z i , P. A., S h i e l d s , P. G., C l a r k , G., L u c i e r , G. W., G a r t e , S. J., C o s m a , G. andC a p o r a s o , N. E., 1994, Association between CYP1A1 genotype, mRNA expression and
enzymatic activity in humans. Pharmacogenetics, 4, 242± 246.L e G u e l l e c , C., L a c a r e l l e , B., C a t a l i n , J. and D u r a n d , A., 1993, Inhibitory eå ects of anticancer
drugs on dextromethorphan O-demethylase activity in human liver microsomes. CancerChemotherapy and Pharmacology, 32, 491± 495.
L e e , S. S. T., B u t e r s , J. T. M., P i n e a u , T., F e r n a n d e z -S a l g u e r o , P. and G o n z a l e z , F. J., 1996, Roleof CYP2E1 in the hepatotoxicity of acetaminophen. Journal of Biological Chemistry, 271,
12063± 12067.L e e m a n n , T. and D a y e r , P., 1995, Quantitative prediction of in vivo drug metabolism and interactions
from in vitro data. In G. M. Paci® ci and G. N. Fracchia (eds), Advances in Drug Metabolism inMan (Luxembourg : Oæ ce for Oæ cial Publications of the European Communities), pp. 783± 830.
L e e m a n n , T. D., T r a n s o n , C., B o n n a b r y , P. and D a y e r , P., 1993, A major role for cytochrome P450TB
(CYP2C subfamily) in the actions of non-steroida l antiin¯ ammatory drugs. Drugs and Ex-
perimental Clinical Research, XIX , 189± 195.L e o , M. A., L a s k e r , J. M., R a u c y , J. L., K i m , C.-I., B l a c k , M. and L i e b e r , C. S., 1989, Metabolism
of retinol and retinoic acids by human liver cytochrome P450IIC8. Archives of Biochemistry andBiophysics, 269, 305± 312.
L e s c a , P., P e r y t , B., L a r r i e u , G., A l v i n e r i e , M., G a l t i e r , P., D a u j a t , M., M a u r e l , P. andH o o g e n b o o m , L., 1995, Evidence for the ligand-independent activation of the Ah receptor.
Biochemical and Biophysical Research Communications, 209, 474± 482.
1248 O. Pelkonen et al.
L e v i n , W., 1990, Functional diversity of hepatic cytochromes P-450. Drug Metabolism and Disposition,18, 824± 830.
L i , A. P., R a s m u s s e n , A., X u , L. and K a m i n s k i , D. L., 1995, Rifampicin induction of lidocaine
metabolism in cultured human hepatocytes. Journal of Pharmacology and Experimental Thera-peutics, 274, 673± 677.
L i a n g , H.-C. L., L i , H., M c K i n n o n , R. A., D u f f y , J. J., P o t t e r , S. S., P u g a , A. and N e b e r t , D. W.,1996, CYP1a2( – } –) null mutant mice develop normally but show de® cient drug metabolism.
Proceedings of the National Academy of Sciences, USA, 93, 1671± 1676.L i e b e r , C. S., 1997, Cytochrome P-4502E1 : its physiological and pathological role. Physiological
Reviews, 77, 517± 544.L i e b e r , C. S. and D e c a r l i , L. M., 1968, Ethanol oxidation by hepatic microsomes : adaptive increase
after ethanol feeding. Science, 162 , 917± 918.L i n d r o s , K. O., 1997, Zonation of cytochrome P450 expression, drug metabolism and toxicity in liver.
General Pharmacology, 28, 191± 196.L o p e z G a r c i a , M. P., D a n s e t t e , P. M., V a l a d o n , P., A m a r , C., B e a u n e , P., G u e n g e r i c h , F. P. and
M a n s u y , D., 1993, Human liver P450s expressed in yeast as tools for reactive metaboliteformation studies : oxidative activation of tienilic acid by P450 2C9 and P450 2C10. European
Journal of Biochemistry, 213, 223± 232.L o w n , K. S., B a i l e y , D. G., F o n t a n a , R. J., J a n a r d a n , S. K., A d a i r , C. H., F o r t l a g e , L. A., B r o w n ,
M. B., G u o , W. and W a t k i n s , P. B., 1997, Grapefruit juice increases felodipine oral availabilityin humans by decreasing intestinal CYP3A protein expression. Journal of Clinical Investigation,99, 2545± 2553.
L o w n , K. S., T h u m m e l , K. E., B e n e d i c t , P. E., S h e n , D. D., T u r g e o n , D. K., B e r e n t , S. and
W a t k i n s , P. B., 1995, The erythromycin breath test predicts the clearance of midazolam. ClinicalPharmacology and Therapeutics, 57, 16± 24.
L u c a s , D., M e n e z , C., G i r r e , C., B e r t h o u , F., B o d e n e z , P., J o a n n e t , I., H i s p a r d , E., B a r d o u , L.-G.and M e n e z , J.-F., 1995, Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in
healthy and alcoholic Caucasian subjects. Pharmacogenetics, 5, 298± 304.M a h g o u b , A., I d l e , J. R., D r i n g , L. G., L a n c e s t e r , R. and S m i t h , R. L., 1977, Polymorphic
hydroxylation of debrisoquine in man. Lancet, ii, 584± 586.M a n d e m a , J. W., T u k , B., v a n S t e v e n i c k , A. L., B r e i m e r , D. D., C o h e n , A. F. and D a n h o f , M., 1992,
Pharmacokinetic-pharmacodynamic modelling of the central nervous system eå ects of midazolamand its main metabolite a-hydroxymidazolam in healthy volunteers. Clinical Pharmacology and
Therapeutics, 51 , 715± 728.M a $ e n p a $ a $ , J., H a l l , S. D., R i n g , B. J., S t r o m , S. C. and W r i g h t o n , S. A., 1998, Human cytochrome
P450 3A (CYP3A) mediated midazolam metabolism : the eå ect of assay conditions andregioselective stimulation by a-naphtho¯ avone, terfenadine and testosterone. Pharmacogenetics
(in press).M a z z e , R. I., W o o d r u f f , R. E. and H e e r d t , M. E., 1982, Isoniazid-induced en¯ urane de¯ uorination in
humans. Anesthesiology, 57, 5± 8.M c D o n n e l l , W. M., S c h e i m a n , J. M. and T r a b e r , P. G., 1992, Induction of cytochrome P450IA genes
(CYP1A) by omeprazole in the human alimentary tract. Gastroentero logy, 103, 1509± 1516.M c G e h e e , R. E., R o n i s , M. J. J. and B a d g e r , T. M., 1997, Regulation of the hepatic CYP 2E1 gene
during chronic alcohol exposure : lack of an ethanol response element in the proximal 5´-¯ ankingsequence. DNA and Cell Biology, 16, 725± 736.
M e y e r , U. A., 1994, Pharmacogenetics : the slow, the rapid, and the ultrarapid. Proceedings of theNational Academy of Sciences, USA, 91, 1983± 1984.
M e y e r , U. A., S k o d a , R. C. and Z a n g e r , U. M., 1990, The general polymorphism ofdebrisoquine } sparteine metabolism-molecular mechanisms. Pharmacology and Therapeutics, 46,
297± 308.M i c k a , J., M i l a t o v i c h , A., M e n o n , A., G r a b o w s k i , G. A., P u g a , A. and N e b e r t , D. W., 1997, Human
Ah receptor (AHR) gene : localization to 7p15 and suggestive correlation of polymorphism withCYP1A1 inducibility. Pharmacogenetics , 7 , 95± 101.
M o l o w a , D. T., S c h u e t z , E. G., W r i g h t o n , S. A., W a t k i n s , P. B., K r e m e r s , P., M e n d e z -P i c o n , G.,P a r k e r , G. A. and G u z e l i a n , P. S., 1986, Complete cDNA sequence of a cytochrome P-450
inducible by glucocorticoids in human liver. Proceedings of the National Academy of Sciences,USA, 83, 5311± 5315.
M o r e l , F., B e a u n e , P. H., R a t a n a s a v a n h , D., F l i n o i s , J.-P., Y a n g , C. S., G u e n g e r i c h , F. P. andG u i l l o u z o , A., 1990, Expression of cytochrome P-450 enzymes in cultured human hepatocytes.
European Journal of Biochemistry, 191, 437± 444.M u r r a y , M., 1987, Mechanisms of the inhibition of cytochrome P450-mediated drug oxidation by
therapeutic agents. Drug Metabolism Reviews, 18 , 55± 81.M u r r a y , M., 1992, P450 enzymes ; inhibition mechanisms, genetic regulation and eå ects of liver disease.
Clinical Pharmacokinetics, 23, 123± 146.
P450 inhibition and induction in man 1249
M u s t a j o k i , P., H i m b e r g , J. J., T o k o l a , O. and T e n h u n e n , R., 1992, Rapid normalization of antipyrine
oxidation by heme in variegate porphyria. Clinical Pharmacology and Therapeutics, 51, 320± 324.N a r i m a t s u , S., K a r i y a , S., I s o z a k i , S., O h m o r i , S., K i t a d a , M., H o s o k a w a , S., M a s u b u c h i , Y. and
S u z u k i , T., 1993, Involvement of CYP2D6 in oxidative metabolism of cinnarizine and ¯ unarizinein human liver microsomes. Biochemical and Biophysical Research Communications, 193,
1262± 1268.N e b e r t , D. W., 1989, The Ah locus : genetic diå erences in toxicity, cancer, mutation, and birth defects.
Critical Reviews in Toxicology, 20, 137± 152.N e b e r t , D. W., 1991, Role of genetics and drug metabolism in human cancer risk. Mutation Research ,
247, 267± 281.N e l s o n , S. D., 1990, Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Seminars
in Liver Diseases, 10, 267± 278.N e m e r o f f , C. B., D e v a n e , C. L. and P o l l o c k , B. G., 1996, New antidepressants and the cytochrome
P450 system. American Journal of Psychiatry, 153, 311± 320.N o u s b a u m , J. B., B e r t h o u , F., C a r l h a n t , D., R i c h e , C., R o b a s z k i e w i c z , M. and G o u e r o u , H., 1994,
Four-week treatment with omeprazole increases the metabolism of caå eine. American Journal ofGastroentero logy, 89 , 371± 375.
O’ S h e a , D., K i m , R. B. and W i l k i n s o n , G. R., 1997, Modulation of CYP2E1 activity by isoniazid inrapid and slow N-acetylators. British Journal of Clinical Pharmacology, 43, 99± 103.
O h n h a u s , E. E., B r e c k e n r i d g e , A. M. and P a r k , B. K., 1989, Urinary excretion of 6b-hydroxycortisoland the time course measurement of enzyme induction in man. European Journal of Clinical
Pharmacology, 36 , 39± 46.O l k k o l a , K. T., A r a n k o , K., L u u r i l a , H., H i l l e r , A., S a a r n i v a a r a , L., H i m b e r g , J.-J. and
N e u v o n e n , P. J., 1993, A potentially hazardous interaction between midazolam and erythromycinin healthy volunteers. Clinical Pharmacology and Therapeutics, 53, 298± 305.
O l k k o l a , K. T., B a c k m a n , J. F. and N e u v o n e n , P. J., 1994, Midazolam should be avoided in patientsreceiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and
Therapeutics, 55 , 481± 485.O n o , S., H a t a n a k a , T., H o t t a , H., T s u s t s u i , M., S a t o h , T. and G o n z a l e z , F. J., 1995, Chlorzoxazone
is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics , 5, 143± 150.P a i n e , M. F., S h e n , D. D., K u n z e , K. L., P e r k i n s , J. D., M a r s h , C. L., M c V i g a r , J. P., B a r r , D. M.,
G i l l i e s , B. S. and T h u m m e l , K. E., 1996, First-pass metabolism of midazolam by the humanintestine. Clinical Pharmacology and Therapeutics, 60 , 14± 24.
P a r k , B. K. and B r e c k e n r i d g e , A. M., 1981, Clinical implications of enzyme induction and enzymeinhibition. Clinical Pharmacokinetics, 6, 1± 24.
P a r k , B. K., K i t t e r i n g h a m , N. R., P i r m o h a m e d , M. and T u c k e r , G. T., 1996, Relevance of inductionof human drug-metabolizing enzymes : pharmacological and toxicological implications. British
Journal of Clinical Pharmacology, 41 , 477± 491.P a s a n e n , M. and P e l k o n e n , O., 1994, The expression and environmental regulation of P450 enzymes
in human placenta. Critical Reviews in Toxicology, 24, 211± 229.P a t s a l o s , P. N. and D u n c a n , J. S., 1993, Antiepileptic drugs. A review of clinically signi® cant drug
interactions. Drug Safety, 3, 156± 184.P a t t e n , C., T h o m a s , P. E., G u y , R., L e e , M., G o n z a l e z , F. J., G u e n g e r i c h , F. P. and Y a n g , C. S.,
1993, Cytochrome P450 enzymes involved in acetaminophen activation by rat and human livermicrosomes and their kinetics. Chemical Research in Toxicology, 6, 511± 518.
P e a r c e , R., G r e e n w a y , D. and P a r k i n s o n , A., 1992, Species diå erences and interindividual variation inliver microsomal cytochrome P450 2A enzymes : e å ects on coumarin, dicumarol, and testosterone
oxidation. Archives of Biochemistry and Biophysics, 298, 211± 225.P e l k o n e n , O. and B r e i m e r , D. D., 1994, Role of environmental factors in the pharmacokinetics of
drugsÐ considerations with respect to animal models. In P. G. Welling and L. P. Balant (eds),Handbook of Experimental Pharmacology (Basel : Karger), pp. 289± 332.
P e l k o n e n , O. and R a u n i o , H., 1997, Metabolic activation of toxins : tissue-speci® c expression andmetabolism in target organs. Environmental Health Perspectives , 105 , 767± 774.
P e n n o , M. B. and V e s e l l , E. S., 1983, Monogenic control of variations in antipyrine metaboliteformation. New polymorphism of hepatic drug oxidation. Journal of Clinical Investigation, 71,
1698± 1709.P e r r o t , N., N a l p a s , B., Y a n g , C. S. and B e a u n e , P. H., 1989, Modulation of cytochrome P450 isozymes
in human liver, by ethanol and drug intake. European Journal of Clinical Investigation, 19,549± 555.
P e r s s o n , I., J o h a n s s o n , I. and I n g e l m a n -S u n d b e r g , M., 1997, In vitro kinetics of two human CYP1A1variant enzymes suggested to be associated with interindividual diå erences in cancer sus-
ceptibility. Biochemical and Biophysical Research Communications, 231 , 227± 230.P e r u c c a , E., 1978, Clinical consequences of microsomal enzyme induction by antiepileptic drugs.
Pharmacology and Therapeutics, 2, 285± 314.P e s s a y r e , D., T i n e l , M., L a r r e y , D., C o b e r t , B., F u n k -B r e n t a n o , C. and B a b a n y , G., 1983,
1250 O. Pelkonen et al.
Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione.
Journal of Pharmacology and Experimental Therapeutics, 224 , 685± 691.P e t e r , R., B o $ c k e r , R. G., B e a u n e , P. H., I w a s a k i , M., G u e n g e r i c h , F. P. and Y a n g , C.-S., 1990,
Hydroxylation of chlorzoxazone as a speci® c probe for human liver cytochrome P-450 IIE1.Chemical Research in Toxicology, 3, 566± 573.
P e t e r s e n , D. D., M c K i n n e y , C. E., I k e y a , K., S m i t h , H. H., B a l e , A. E., M c B r i d e , O. W. andN e b e r t , D. W., 1991, Human CYP1A1 gene : cosegregation of the enzyme inducibility phenotype
and an RFLP. American Journal of Human Genetics, 48, 720± 725.P e t e r s e n , K. U., 1995, Review article : Omeprazole and the cytochrome P450 system. Alimentary
Pharmacology and Therapeutics, 9, 1± 9.P i c h a r d , L., F a b r e , I., D a u j a t , M., D o m e r g u e , J., J o y e u x , H. and M a u r e l , P., 1992, Eå ect of
corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity inprimary cultures of human hepatocytes. Molecular Pharmacology, 41, 1047± 1055.
P i c h a r d , L., F a b r e , I., F a b r e , G., D o m e r g u e , J., S a i n t A u b e r t , B., M o u r a d , G. and M a u r e l , P., 1990,Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450
(cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. DrugMetabolism and Disposition, 18, 595± 606.
P i n e a u , T., F e r n a n d e z -S a l g u e r o , P., L e e , S. S. T., M c P h a i l , T., W a r d , J. M. and G o n z a l e z , F. J.,1995, Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 IA2.
Proceedings of the National Academy of Sciences, USA, 92, 5134± 5138.P o u l s e n , H. E. and L o f t , S., 1988, Antipyrine as a model drug to study hepatic drug metabolizing
capacity. Journal of Hepatology, 6, 374± 382.P r e s c o r n , S. H., 1993, Recent pharmacological advances in antidepressant therapy for the elderly.
Americal Journal of Medicine, 94 , 2S± 12S.P u u r u n e n , J., S o t a n i e m i , E. and P e l k o n e n , O., 1980, Eå ect of cimetidine on microsomal drug
metabolism in man. European Journal of Clinical Pharmacology, 18 , 185± 187.Q u a t t r o c h i , L. C. and T u k e y , R. H., 1993, Nuclear uptake of the Ah (dioxin) receptor in response to
omeprazole : transcriptional activation of the human CYP1A1 gene. Molecular Pharmacology, 43,504± 508.
Q u a t t r o c h i , L. C., V u , T. and T u k e y , R. H., 1994, The human CYP1A2 gene and induction by 3-methylcholanthrene, a region of DNA that supports Ah-receptor binding and promoter-speci® c
induction. Journal of Biological Chemistry, 269, 6949± 6954.R a s m u s s e n , B. B., M a $ e n p a $ a $ , J., P e l k o n e n , O., L o f t , S., P o u l s e n , H. E., L y k k e s f e l d t , J. and B r o s e n ,
K., 1995, Selective serotonin reuptake inhibitors and theophylline metabolism in human livermicrosomes : potent inhibition by ¯ uvoxamine. British Journal of Clinical Pharmacology, 39,
151± 159.R a u n i o , H., P a s a n e n , M., M a $ e n p a ! a ! , J., H a k k o l a , J. and P e l k o n e n , O., 1995, Expression of
extrahepatic cytochrome P450 in humans. In G. M. Paci® ci and G. N. Fracchia (eds), Advancesin Drug Metabolism in Man (Luxembourg : European Commission, Oæ ce for Oæ cial Publications
of the European Communities), pp. 234± 287.R a u t i o , A., S a l m e l a , E., A r v e l a , P., P e l k o n e n , O., S o t a n i e m i , E. A., 1994, Assessment of CYP2A6
and CYP3A4 activities in vivo in diå erent diseases in man. In M. C. Lechner (ed.), CytochromeP450. Biochemistry, Biophysics and Molecular Biology (Paris : John Libbey Eurotext), pp. 519± 521.
R e l l i n g , M. V., A o y a m a , T., G o n z a l e z , F. J. and M e y e r , U. A., 1990, Tolbutamide and mephenytoinhydroxylation by human cytochrome P450s in the CYP2C subfamily. Journal of Pharmacology
and Experimental Therapeutics, 252 , 442± 447.R e l l i n g , M. V., E v a n s , W. E., F o n n e -P f i s t e r , R. and M e y e r , U. A., 1989, Anticancer drugs as
inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoinhydroxylase, in human liver microsomes. Cancer Research, 49, 68± 71.
R e t t i e , A. E., E d d y , A. C., H e i m a r k , L. D., G i b a l d i , M. and T r a g e r , W. F., 1989, Characteristics ofwarfarin hydroxylation catalyzed by human liver microsomes. Drug Metabolism and Disposition,17, 265± 270.
R e t t i e , A. E., K o r z e k w a , R., K u n z e , K. L., L a w r e n c e , R. F., E d d y , A. C., A o y a m a , T., G e l b o i n ,
H. V., G o n z a l e z , F. J. and T r a g e r , W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450 : a role for P-4502C9 in the etiology of (S)-warfarin-drug
interactions. Chemical Research in Toxicology, 5, 54± 59.R i z z o , N., P a d o i n , C., P a l o m b o , S., S c h e r r m a n n , J.-M. and G i r r e , C., 1996, Omeprazole and
lansoprazole are not inducers of cytochrome P450IA2 under conventional therapeutic conditions.European Journal of Clinical Pharmacology, 49, 491± 495.
R o b s o n , R. A., M a t t h e w s , A. P., M i n e r s , J. O., M c M a n u s , M. E., M e y e r , U. A., d e l a M. H a l l , P.and B i r k e t t , D. J., 1987, Characterisation of theophylline metabolism in human liver micro-
somes. British Journal of Clinical Pharmacology, 24, 293± 300.R o c h a t , B., A m e y , M., G i l l e t , M., M e y e r , U. A. and B a u m a n n , P., 1997, Identi® cation of three
cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in humanliver microsomes. Pharmacogenetics, 7, 1± 10.
P450 inhibition and induction in man 1251
R o d r i g u e s , A. D., 1994, Use of in vitro human metabolism studies in drug development. An industrial
perspective. Biochemical Pharmacology, 48, 2147± 2156.R o d r i g u e s , A. D., K u k u l k a , M. J., R o b e r t s , E. M., O u e l l e t , D. and R o d g e r s , T. R., 1996, [O-methyl
" % C]naproxen O-demethylase activity in human liver microsomes. Evidence for the involvementof cytochrome P4501A2 and P4502C9 } 10. Drug Metabolism and Disposition, 24 , 126± 136.
R o d r i g u e s , A. D. and R o b e r t s , E. M., 1997, The in vitro interaction of dexmedetomidine with humanliver microsomal cytochrome P4502D6 (CYP2D6). Drug Metabolism and Disposition, 25, 651± 655.
R o n i s , M. J. J., L i n d r o s , K. O. and I n g e l m a n -S u n d b e r g , M., 1996, The CYP2E subfamily. In C.Ioannides (ed.), Cytochromes P450: Metabolic and Toxicological Aspects 211± 239.
R o o t s , I., H o l b e , E., H o v e r m a n n , W., N i g a n , S., H e i n e m y e r , G. and H i l d e b r a n d t , A. G., 1979,Quantitative determination by HPLC of urinary 6b-hydroxycortisol, an indicator of enzyme
induction by rifampicin and antiepileptic drugs. European Journal of Clinical Pharmacology, 16,63± 71.
R o s t , K. L., B r o $ s i c k e , H., B r o c k m o $ l l e r , J., S c h e f f l e r , M., H e l g e , H. and R o o t s , I., 1992, Increaseof cytochrome P450IA2 activity by omeprazole : evidence by the " $ C[N-3-methyl]-caå eine breath
test in poor and extensive metabolizers of S-mephenytoin. Clinical Pharmacology and Thera-peutics, 52 , 170± 180.
R o s t , K. L., B r o $ s i c k e , H., H e i n e m y e r , G. and R o o t s , I., 1994, Speci® c and dose-dependent enzymeinduction by omeprazole in human beings. Hepatology, 20, 1204± 1212.
R o s t , K. L. and R o o t s , I., 1994, Accelerated caå eine metabolism after omeprazole treatment isindicated by urinary metabolite ratios : coincidence with plasma clearance and breath test. Clinical
Pharmacology and Therapeutics, 55, 402± 411.S a r i c h , T., K a l h o r n , T., M a g e e , S., A l -S a y e g h , F., A d a m s , S., S l a t t e r y , J., G o l d s t e i n , J., N e l s o n ,
S. and W r i g h t , J., 1997, The eå ect of omeprazole pretreatment on acetaminophen metabolism inrapid and slow metabolizers of S-mephenytoin. Clinical Pharmacology and Therapeutics, 62,
21± 28.S c h m i d e r , J., G r e e n b l a t t , D. J., v o n M o l t k e , L. L., H a r m a t z , J. S. and S h a d e r , R. I., 1995, N-
demethylation of amitriptyline in vitro : role of cytochrome P-450 3A (CYP3A) isoforms and eå ectof metabolic inhibitors. Journal of Pharmacology and Experimental Therapeutics, 275, 592± 597.
S c h m i d t , J. V. and B r a d f i e l d , C. A., 1996, Ah receptor signalling pathways. Annual Review of CellularDevelopment and Biology, 12 , 55± 89.
S c h u e t z , E. G., B e c k , W. T. and S c h u e t z , J. D., 1996, Modulators and substrates of P-glycoproteinand cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
Molecular Pharmacology, 49 , 311± 318.S c h u e t z , E. G., S c h u e t z , J. D., S t r o m , S. C., T h o m p s o n , M. T., F i s h e r , R. A., M o l o w a , D. T., L i ,
D. and G u z e l i a n , P. S., 1993, Regulation of human liver cytochromes P-450 in family 3A inprimary and continuous culture of human hepatocytes. Hepatology, 18, 1254± 1262.
S c h u e t z , J. D., S c h u e t z , E. G., T h o t t a s s e r y , J. V., G u z e l i a n , P. S., S t r o m , S. and S u n , D., 1996,Identi® cation of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its
activation in human and rat liver cells. Molecular Pharmacology, 49, 63± 72.S e s a r d i c , D., P a s a n e n , M., P e l k o n e n , O. and B o o b i s , A. R., 1990, Diå erential expression and
regulation of the members of the cytochrome P450IA gene subfamily in human tissues.Carcinogenesis, 11 , 1183± 1188.
S h a r e r , J. E. and W r i g h t o n , S. A., 1996, Identi® cation of the human hepatic cytochromes P450involved in the in vitro oxidation of antipyrine. Drug Metabolism and Disposition, 24 , 487± 494.
S h i m a d a , T., H a y e s , C. L., Y a m a z a k i , H., A m i n , S., H e c h t , S. S., G u e n g e r i c h , F. P. and S u t t e r ,T. R., 1996, Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1.
Cancer Research , 56, 2979± 2984.S h i m a d a , T., M i s o n o , K. S. and G u e n g e r i c h , F. P., 1986, Human liver microsomal cytochrome P-450
mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism :puri® cation and characterization of two similar forms involved in the reaction. Journal of
Biological Chemistry, 261 , 909± 921.S h i m a d a , T., Y a m a z a k i , H., M i m u r a , M., I n u i , Y. and G u e n g e r i c h , F. P., 1994, Interindividual
variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs,carcinogens and toxic chemicals : studies with liver microsomes of 30 Japanese and 30 Caucasians.
Journal of Pharmacology and Experimental Therapeutics, 270 , 414± 423.S h i m i z u , M., L a s k e r , J. M., T s u t s u m i , M. and L i e b e r , C. S., 1990, Immunohistochemical localization
of ethanol-inducible P450IIE1 in the rat alimentary tract. Gastroenterology, 99 , 1044± 1053.S h o u , M., G r o g a n , J., M a n c e w i c z , J. A., K r a u s z , K. W., G o n z a l e z , F. J., G e l b o i n , H. V. and
K o r z e k w a , K. R., 1994, Activation of CYP3A4 : evidence for the simultaneous binding of twosubstrates in a cytochrome P450 active site. Biochemistry , 33, 6450± 6455.
S i m p s o n , A. E. C. M., 1997, The cytochrome P450 (CYP4) family. General Pharmacology, 28, 351± 359.S o n n i c h s e n , D. S., L i e , O., S c h u e t z , E. G., S c h u e t z , J. D., P a p p o , A. and R e l l i n g , M. V., 1995,
Variability in human cytochrome P450 paclitaxel metabolism. Journal of Pharmacology andExperimental Therapeutics, 275 , 566± 575.
1252 O. Pelkonen et al.
S o o n s , P. A., V o g e l s , B. A. P. M., R o o s e m a l e n , M. C. M., S c h o e m a k e r , H. C., U c h i d a , E., E d g a r ,
B., L u n d a h l , J., C o h e n , A. F. and B r e i m e r , D. D., 1991, Grapefruit juice and cimetidine inhibitstereoselective metabolism of nitrendipine in humans. Clinical Pharmacology and Therapeutics,50, 394± 403.
S o t a n i e m i , E. A. and P e l k o n e n , R. O. (eds), 1987, Enzyme Induction in Man (London : Taylor &
Francis).S o u c e k , P. and G u t , I., 1992, Cytochromes P-450 in rats ± structures, functions, properties and relevant
human forms. Xenobiotica , 22, 83± 104.S t e v e n s , J. C. and W r i g h t o n , S. A., 1993, Interactions of the enantiomers of ¯ uoxetine and
nor¯ uoxetine with human liver cytochromes P450. Journal of Pharmacology and ExperimentalTherapeutics, 266, 964± 971.
S t o c k l e y , I. H., 1996, Theophylline and related xanthine drug interactions. In Drug Interactions, 4thedn (London : Pharmaceutical Press), pp. 767± 804.
S u t t e r , T. R., T a n g , Y. M., H a y e s , C. L., W o , Y.-Y. P., J a b s , E. W., L i , X., Y i n , H., C o d y , C. W. andG r e e n l e e , W. F., 1994, Complete cDNA sequence of a human dioxin-inducible mRNA identi® es
a new gene subfamily of a cytochrome that maps to chromosome 2. Journal of Biological Chemistry,269, 13092± 13099.
T a k a h a s h i , T., L a s k e r , J. M., R o s m a n , A. S. and L i e b e r , C. S., 1993, Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger
RNA. Hepatology, 17, 236± 245.T a r r u s , E., C a m i , J., R o b e r t s , D. J., S p i c k e t t , R. G. W., G e l d r a n , E. and S e g u r a , J., 1987,
Accumulation of caå eine in healthy volunteers treated with furafylline. British Journal of ClinicalPharmacology, 23 , 9± 18.
T e s t a , B. and J e n n e r , P., 1981, Inhibitors of cytochrome P450s and their mechanism of action. DrugMetabolism Reviews, 12, 1± 118.
T h u m m e l , K. E., S h e n , D. D., P o d o l l , T. D., K u n z e , K. L., T r a g e r , W. F., B a c c h i , C. E., M a r s h ,C. L., M c V i g a r , J. P., B a r r , D. M., P e r k i n s , J. D. and C a r i t h e r s , R. L., 1994a, Use of
midazolam as a human cytochrome P450 3A probe : II. Characterization of inter- andintraindividual hepatic CYP3A variability after liver transplantation. Journal of Pharmacology and
Experimental Therapeutics, 271 , 557± 566.T h u m m e l , K. E., S h e n , D. D., P o d o l l , T. D., K u n z e , K. L., T r a g e r , W. F., H a r t w e l l , P. S., R a i s y s ,
V. A., M a r s h , C. L., M c V i g a r , J. P., B a r r , D. M., P e r k i n s , J. D. and C a r i t h e r s , R. L., 1994b,Use of midazolam as a human cytochrome P450 3A probe : I. In vitro± in vivo correlations in liver
transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271, 549± 556.T r a c y , T. S., M a r r a , C., W r i g h t o n , S. A., G o n z a l e z , F. J. and K o r z e k w a , K. R., 1997, Involvement
of multiple cytochrome P450 isoforms in naproxen O-demethylation. European Journal of ClinicalPharmacology, 52 , 293± 298.
T r a n s o n , C., L e c o e u r , S., L e e m a n n , T., B e a u n e , P. and D a y e r , P., 1996, Interindividual variability incatalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes.
European Journal of Clinical Pharmacology, 51, 79± 85.T s u t s u m i , M., L a s k e r , J. M., S h i m i z u , M., R o s m a n , A. S. and L i e b e r , C. S., 1989, The intralobular
distribution of ethanol-inducible P-450IIE1 in rat and human liver. Hepatology, 10 , 437± 446.V e r o n e s e , M. E., M a c K e n z i e , P. I., D o e c k e , C. J., M c M a n u s , M. E., M i n e r s , J. O. and B i r k e t t ,
D. J., 1991, Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cyto-chrome P4502C9. Biochemical and Biophysical Research Communications, 175 , 1112± 1118.
V e r o n e s e , M. E., D o e c k e , C. J., M a c K e n z i e , P. I., M c M a n u s , M. E., M i n e r s , J. O., R e e s , D. L. P.,G a s s e r , R., M e y e r , U. A. and B i r k e t t , D. J., 1993, Site-directed mutation studies of human liver
cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal, 289, 533± 538.v o n M o l t k e , L. L., G r e e n b l a t t , D. J., C o t r e a u -B i b b o , M. M., D u a n , S. X., H a r m a t z , J. S. and
S h a d e r , R. I., 1994, Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole : a model system to predict drug
interactions in vivo. Journal of Pharmacology and Experimental Therapeutics, 268, 1278± 1283.v o n M o l t k e , L. L., G r e e n b l a t t , D. J., H a r m a t z , J. S., D u a n , S. X., H a r r e l , L. M., C o t r e a u -B i b b o ,
M. M., P r i t c h a r d , G. A., W r i g h t , C. E. and S h a d e r , R. I., 1996, Triazolam biotransformationby human liver microsomes in vitro : e å ects of metabolic inhibitors and clinical con® rmation of a
predicted interaction with ketoconazole. Journal of Pharmacology and Experimental Therapeutics,276, 370± 379.
W a t a n a b e , J., H a y a s h i , S. and K a w a j i r i , K., 1994, Diå erent regulation and expression of the humanCYP2E1 gene due to the RsaI polymorphism in the 5´ ¯ anking region. Journal of Biochemistry,116, 321± 3256.
W a t k i n s , P. B., M u r r a y , S. A., W i n k e l m a n , L. G., H e u m a n , D. M., W r i g h t o n , S. A. and G u z e l i a n ,
P. S., 1989, Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Journal of Clinical Investigation, 83, 688± 697.
W a t k i n s , P. B., W r i g h t o n , S. A., M a u r e l , P., S c h u e t z , E. G., M e n d e z -P i c o n , G., P a r k e r , G. A. and
P450 inhibition and induction in man 1253
G u z e l i a n , P. S., 1985, Identi® cation of an inducible form of cytochrome P-450 in human liver.
Proceedings of the National Academy of Sciences, USA, 82, 6310± 6314.W a t k i n s , P. B., 1994, Noninvasive tests of CYP3A enzymes. Pharmacogenetics, 4, 171± 184.
W a x m a n , D. J. and A z a r o f f , L., 1992, Phenobarbital induction of cytochrome P-450 gene expression.Biochemical Journal, 281, 577± 592.
W a x m a n , D. J., K o , A. and W a l s h , C., 1983, Radioselectivity and stereoselectivity of androgenhydroxylations catalysed by cytochrome P-450 isozymes puri® ed from phenobarbital induced rat
liver. Journal of Biological Chemistry, 258, 11937± 11947.W a x m a n , D. J., L a p e n s o n , D. P., A o y a m a , T., G e l b o i n , H. V., G o n z a l e z , F. J. and K o r z e k w a , K.,
1991, Steroid hormone hydroxylase speci® cities of eleven cDNA-expressed human cytochromeP450s. Archives of Biochemistry and Biophysics, 290 , 160± 166.
W e d l u n d , P. J., A s l a n i a n , W. S., M c A l l i s t e r , C. B., W i l k i n s o n , G. R. and B r a n c h , R. A., 1984,Mephenynotoin hydroxylation de® ciency in caucasians : frequency of a new oxidative drug
metabolism polymorphism. Clinical Pharmacology and Therapeutics, 36 , 773± 780.W e d l u n d , P. J., K i m u r a , S., G o n z a l e z , F. J. and N e b e r t , D. W., 1994, 1462V mutation in the human
CYP1A1 gene : lack of correlation with either the Msp I 1.9 kb (M2) allele of CYP1A1 inducibilityin a three-generation family of East Mediterranean descent. Pharmacogenetics, 4, 21± 26.
W i l k i n s o n , G. R., 1996, Cytochrome P4503A (CYP3A) metabolism : prediction of in vivo activity inhumans. Journal of Pharmacokinetics and Biopharmaceutics, 24, 475± 490.
W r i g h t o n , S. A., B r i a n , W. R., S a r i , M. A., I w a s a k i , M., G u e n g e r i c h , F. P., R a u c y , J. L., M o l o w a ,D. T. and V a n d e n b r a n d e n , M., 1990, Studies on the expression and metabolic capabilities of
human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology, 38, 207± 213.W r i g h t o n , S. A., C a m p a n i l e , C., T h o m a s , P. E., M a i n e s , S. L., W a t k i n s , P. B., P a r k e r , G., M e n d e z -
P i c o n , G., H a n i u , M., S h i v e l y , J., L e v i n , W. and g u z e l i a n , P. S., 1986, Identi® cation of ahuman liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450
in the rat. Molecular Pharmacology, 29 , 405± 410.W r i g h t o n , S. A. and R i n g , B. J., 1994, Inhibition of human CYP3A catalyzed 1´-hydroxy midazolam
formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. PharmaceuticalResearch , 11 , 921± 924.
W r i g h t o n , S. A., R i n g , B. J., W a t k i n s , P. B. and V a n d e n b r a n d e n , M., 1989, Identi® cation of apolymorphically expressed member of the human cytochrome P-450III family. Molecular
Pharmacology, 86 , 97± 105.W r i g h t o n , S. A. and S t e v e n s , J. C., 1992, The human hepatic cytochromes P450 involved in drug
metabolism. Critical Reviews in Toxicology, 22, 1± 21.W r i g h t o n , S. A., T h o m a s , P. E., W i l l i s , P., M a i n e s , S. L., W a t k i n s , P. B., L e v i n , W. and G u z e l i a n ,
P. S., 1987, Puri® cation of a human liver cytochrome P-450 immunochemically related to severalcytochromes P-450 puri® ed from untreated rats. Journal of Clinical Investigation, 80 , 1017± 1022.
Y a m a z a k i , H., G u o , Z., P e r s m a r k , M., M i m u r a , M., I n o u e , K., G u e n g e r i c h , F. P. and S h i m a d a , T.,1994, Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver
microsomes. Molecular Pharmacology, 46, 568± 577.Y a n g , C. S., B r a d y , J. F. and H o n g , J.-Y., 1992, Dietary eå ects on cytochromes P450, xenobiotic
metabolism, and toxicity. FASEB Journal, 6, 737± 744.Z a n d , R., N e l s o n , S. D., S l a t t e r y , J. T., T h u m m e l , K. E., K a l h o r n , T. F., A d a m s , S. P. and
W r i g h t , J. M., 1993, Inhibition and induction of ch P4502E1-catalyzed oxidation by isoniazid inhumans. Clinical Pharmacology and Therapeutics, 54 , 142± 149.
Z h a n g , Z.-Y., F a s c o , M. J., H u a n g , L., G u e n g e r i c h , F. P. and K a m i n s k y , L. S., 1996, Charac-terization of puri® ed human recombinant cytochrome P4501A1-Ile % ’ # and -Val% ’ # : assessment of
a role for the rare allele in carcinogenesis. Cancer Research , 56 , 3926± 3933.Z i m m e r m a n , H. J. and M a d d r e y , W. C., 1995, Acetaminophen (paracetamol) hepatotoxicity with
regular intake of alcohol : analysis of instances of therapeutic misadventure. Hepatology, 22,767± 773.